

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

**The CONcussion in non-aThletes; Assessment of CognITion and Symptomatology (CONTACTS) study: An exploratory cohort study investigating the utility of sports concussion assessment tools and salivary micro-RNAs to diagnose concussion in NHS patients**

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-062030
Article Type:	Protocol
Date Submitted by the Author:	16-Feb-2022
Complete List of Authors:	Toman, Emma; University of Birmingham; University Hospitals Birmingham NHS Foundation Trust Riley, Max; University of Birmingham, Medical School Hodgson, Sam; University of Birmingham, Medical School Yakoub, Kamal; University Hospitals Birmingham NHS Foundation Trust, NIHR SRMRC Cooper, Lauren; University Hospitals Birmingham NHS Foundation Trust Bishop, Jon; University of Birmingham, Medical Statistician Naumann, David; Royal Centre for Defence Medicine; University Hospitals Birmingham NHS Foundation Trust, General Surgery Welbury, Richard; University of Central Lancashire, School of Dentistry Hammond, Douglas; Blackpool Teaching Hospitals NHS Foundation Trust, Department of Oral and Maxillofacial Surgery Di Pietro, V; University of Birmingham belli, antonio; University of Birmingham, Institute of Inflammation and Ageing
Keywords:	ACCIDENT & EMERGENCY MEDICINE, Neurological injury < NEUROLOGY, NEUROSURGERY, TRAUMA MANAGEMENT

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6  
7  
8  
9

# The CONcussion in non-aThletes; Assessment of CogniTion and Symptomatology (CONTACTS) study: An exploratory cohort study investigating the utility of sports concussion assessment tools and salivary micro-RNAs to diagnose concussion in NHS patients

10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

*Emma Toman*,<sup>1,2,3</sup> Max Riley,<sup>4</sup> Sam Hodgson,<sup>4</sup> Kamal M Yakoub,<sup>2</sup> Lauren Cooper,<sup>2</sup> Jonathan RB Bishop,<sup>2,5</sup> David N Naumann,<sup>6,7</sup> Richard Welbury,<sup>8</sup> Douglas Hammond,<sup>9</sup> Valentina Di Pietro,<sup>1</sup> Antonio Belli<sup>1,2,3</sup>

*Corresponding author:*

*Ms Emma Toman*

*4<sup>th</sup> Floor, NIHR Surgical Reconstruction and Microbiology Research Centre, Institute of Translational Medicine, Heritage Building, Mindelsohn Way. Edgbaston, Birmingham, B15 2WB  
ekt635@student.bham.ac.uk*

1. Neurotrauma and Ophthalmology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK
2. NIHR Surgical Reconstruction and Microbiology Research Centre, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
3. Department of Neurosurgery, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
4. College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK
5. Institute of Applied Health Research, University of Birmingham, Birmingham, UK
6. Royal Centre for Defence Medicine, Birmingham, UK
7. Department of General Surgery, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
8. School of Dentistry, University of Central Lancashire, Preston, UK
9. Department of Oral and Maxillofacial Surgery, Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool, UK

**Word count: 3338**

## **ABSTRACT**

### **Introduction:**

Concussion is a complex pathophysiological process with a wide range of non-specific signs and symptoms. There are currently no objective diagnostic tests to identify concussion, and diagnosis relies solely on history and examination. Recent research has identified a unique panel of micro-RNAs (miRNAs) that distinguish between concussed and non-concussed rugby players. This study aims to assess the diagnostic utility of salivary miRNAs in concussion for a sample of NHS patients, and whether well-established sports-related concussion (SRC) assessment tools may be translated into the Emergency Department (ED).

### **Methods and analysis:**

CONTACTS is a single-centre, prospective, two-phase cohort study. The concussed cohort will consist of participants with maxillofacial trauma and concurrent concussion. The control cohort will consist of participants with isolated limb trauma and no evidence of concussion. Saliva samples will be taken to identify the presence of miRNAs. The SRC assessments being investigated include the Sports Concussion Assessment Test version 5 (SCAT5), the Immediate Post-Concussive Assessment and Cognitive Test (ImPACT) and the ImPACT Quick. Follow up will be at 24-48 hours, 14 days and 6 months.

### **Ethics and dissemination:**

Ethical approval was granted in February 2021 by the West Midlands - Coventry & Warwickshire Research Ethics Committee (ref 20/WM/0299).

## **STRENGTHS AND LIMITATIONS OF THIS STUDY**

- Incorporated feasibility phase to ensure the study is correctly powered
- Pragmatic design that allows assessment of potential clinical utility
- Inclusion of older patients and those with mental health conditions or concurrent intoxication
- COVID may limit the amount of time patients are in ED and so the design may need to be adapted
- Those with premorbid neurological or cognitive issues were unable to be included in this study

## **INTRODUCTION**

### **Background and previous literature:**

Concussion is defined as “a complex pathophysiological process affecting the brain, induced by traumatic biomechanical forces”. (1) Signs and symptoms are nonspecific and are largely categorised into physical, cognitive, behavioural and sleep. The Concussion in Sport Group (CISG) provides a clear definition of concussion with clinical criteria that are summarised in Figure 1. (1)

Each year 1.4 million people present to the Emergency Department (ED) in England and Wales with traumatic brain injury (TBI). (2) Since 90% of TBI cases are classified as mild in severity (3) and have an estimated lifetime cost of \$5,299, (4) concussion represents an extensive financial burden and is a substantial public health concern.

Diagnosis remains the main stumbling block in the management of concussion. There is currently no objective diagnostic test in clinical practice to identify the condition, and therefore diagnosis relies solely on history and examination. This poses difficulty where there are no witnesses to the event or the patient suffers existing cognitive, neurological or psychiatric disorders. The CISG has suggested that no single investigation should be used to diagnose concussion. Instead, several techniques should be used in combination with clinical judgement. (1) Two such widely accepted tools include the paper-based Sports Concussion Assessment Tool 5<sup>th</sup> edition (SCAT5) (5) and the computerised neurocognitive Immediate Post-Concussive Assessment and Cognitive Test (ImPACT). (6) Combined, these tools assess a wide variety of domains that can be affected by concussion including physical signs, symptoms, memory, concentration, balance, gait, reaction time and attention.

Selection bias is the most common drawback of applying existing evidence to non-athletes. Older people, those under the influence of alcohol or drugs and patients with existing cognitive, neurological or psychiatric conditions have traditionally been excluded from previous studies. This means that any

1  
2  
3 prior findings may not be applicable to the overall NHS population presenting to services with  
4  
5 concussion.  
6  
7  
8  
9

### 10 11 **Salivary microRNAs (miRNAs)** 12

13  
14  
15 Salivary miRNAs have recently been identified as the most promising biomarker in the identification  
16  
17 of concussion in sport. miRNAs are non-coding fragments of RNA that play an important role in gene  
18  
19 expression. (7) The most significant study so far in the investigation of salivary miRNA was the Study  
20  
21 of Concussion in Rugby Union through MicroRNAs; the “SCRUM study”, results of which were  
22  
23 published in 2021. This study found that a panel of 14 miRNAs successfully identified concussed rugby  
24  
25 players from those with a negative concussion assessment, non-injured controls and musculoskeletal  
26  
27 injured controls. The miRNA panel was able to differentiate between clinically-diagnosed concussion  
28  
29 and clinically-excluded concussion immediately post-match and at 36-48 hours which has significant  
30  
31 implications for use in professional sports. (8) It also demonstrates great promise for use in non-  
32  
33 athletes in the detection of concussion in the ED. Salivary miRNAs are worthy of further investigation  
34  
35 in the non-athlete setting where there is a far greater variation in age, physical and cognitive baseline  
36  
37 characteristics of patients presenting with head injury.  
38  
39  
40  
41  
42  
43  
44

### 45 **Sports Concussion Assessment Tool 5<sup>th</sup> edition (SCAT5)** 46

47  
48 The SCAT5 is the most recent version of the SCAT, based on a systematic review and synthesis of  
49  
50 current research, public input and expert panel review as part of the 5th International Consensus  
51  
52 Conference on Concussion in Sport held in Berlin in 2016. (1) The SCAT5 is validated for assessment of  
53  
54 sports-related concussion in patients 13 years or older and should take no less than 10 minutes to  
55  
56 perform. The assessment should be conducted by healthcare professionals only and is not designed  
57  
58 to be a standalone tool in the diagnosis of concussion.  
59  
60

1  
2  
3 Very few studies using SCAT in non-athlete populations have been published with the vast majority of  
4 data coming from adolescent athletes. A shared finding across non-athlete studies is that symptom  
5 number and severity seem to provide the most diagnostic accuracy for discriminating between  
6 concussed and control patients. (9-13) The balance assessment is not well tolerated in non-athletes  
7 (11) and poses obvious problems where the control sample have suffered limb injury. Very few studies  
8 have reported individual elements of the SCAT assessment, with the majority combining all non-  
9 symptom sections of the test to provide a Standardised Assessment of Concussion (SAC) score.  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22

### 23 **Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT)**

24  
25  
26 The ImPACT tool is a computer-based neurocognitive assessment widely used across a variety of  
27 professional sports. (6) The test should be administered by a healthcare professional and is validated  
28 for patients aged 12-59 years. The test should take 20-25 minutes to administer and considers several  
29 different assessment domains. As with the SCAT5, the ImPACT tools are not designed to be used as a  
30 standalone diagnostic tool. The ImPACT tool includes multiple tests culminating in scores for verbal  
31 memory, visual memory, reaction time, processing speed, impulse control and total symptom score.  
32  
33  
34  
35  
36  
37  
38  
39

40  
41 A recent literature review examining the validity of the ImPACT test revealed that although the tool  
42 demonstrated sound convergent validity, research describing discriminant validity and diagnostic  
43 accuracy was either inconclusive or scanty. (14) This provides support for further studies in this area.  
44  
45  
46 Very few of the studies included in the review concerned the use of ImPACT in non-athlete populations  
47 and three of the sixty-nine studies analysed the use of ImPACT in concussed versus controls suffering  
48 orthopaedic injuries.  
49  
50  
51  
52  
53

54  
55 Non-athlete studies using the ImPACT assessment have produced conflicting results. A 2017 American  
56 study recruited 94 concussed patients and 80 matched-trauma controls from ED and performed  
57 ImPACT assessment within 72 hours of injury, 15 days and 45 days. (15) No significant difference in  
58  
59  
60



1  
2  
3 composite scores were found between groups at any of the time points. By comparison, an Australian  
4 study assessing 79 mild TBI (mTBI) patients to 86 trauma control patients in the ED found significant  
5 differences in all 5 composite domain scores. (16)  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## **RATIONALE**

1  
2  
3  
4  
5  
6 Previous work suggests that concussion remains underdiagnosed in the ED (17, 18) and patients may  
7  
8 not be followed up adequately in clinical practice. (19) This may reflect the complex nature of  
9  
10 diagnosing and monitoring concussion but may also demonstrate the lack of NHS resources allocated  
11  
12 towards mTBI care. Additional common barriers to screening for concussion in NHS patients such as  
13  
14 intoxication and dementia complicate recognition and diagnosis further. (17) It is important therefore  
15  
16 to assess whether well-established SRC assessment tools may be translated into the non-sporting  
17  
18 population of the NHS. To determine whether these tools can be translatable, they must be tested in  
19  
20 groups that are reflective of the patients who suffer concussive injury in the NHS population.  
21  
22 Therefore, elderly and intoxicated patients should also be assessed. A longer-term qualitative review  
23  
24 of the tools would add depth to existing data and indicate the willingness of non-athletes to engage  
25  
26 in these tests using telephone and email reviews.  
27  
28  
29

30  
31 Currently, the National Institute for Health and Care Excellence (NICE) guidelines concerning  
32  
33 mTBI/concussion focus on appropriate triage and acute management of head injury. No guidelines  
34  
35 exist regarding follow-up or referral of patients with ongoing symptoms. More innovative ways of  
36  
37 monitoring recovery and symptoms in such patients need to be developed, ideally remotely. A  
38  
39 concussion assessment that is clinically accurate and that patients can—and want to—perform at  
40  
41 home could revolutionise the possibilities in which secondary care clinicians could manage these  
42  
43 patients.  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## **METHODS AND ANALYSIS**

### **Study Design**

CONTACTS is a prospective cohort study investigating the use of sports concussion assessment tools and the diagnostic utility of salivary miRNAs in concussed versus control adult participants following non-sporting maxillofacial trauma. It will commence with a phase 1, feasibility study followed by a phase 2, substantive study if progression criteria are met. Both phases will take place at the Queen Elizabeth Hospital Birmingham (QEHB) as a single-centre study. Participants will be followed up for a period of 6 months post recruitment.

Patients of interest include adult patients who require hospital admission following non-sporting isolated maxillofacial trauma. Recruiting patients with maxillofacial trauma to the concussion arm ensures that there is objective evidence of head injury having occurred.

### **Eligibility Criteria**

For patients with isolated concussion, the standard clinical care would be discharge from the ED with a responsible adult and suitable head injury advice. To optimise the rate of follow-up of participants, only patients requiring admission will be recruited. To ensure that all participants in the concussion arm have suffered an impact to the head, face or neck (as required for concussion diagnosis according to CISG definition), only patients with maxillofacial injury will be recruited. The control arm will consist of participants having suffered an isolated limb injury. Inclusion and exclusion criteria are summarised in table 1.

**Table 1. Summary of eligibility criteria for the CONTACTS study**

<b>Cohort</b>	<b>Inclusion</b>	<b>Exclusion</b>
---------------	------------------	------------------

1			
2			
3	<i>Both</i>	≥16 years old	Police custody
4			
5		Requires admission to QEHB	Prisoner
6			
7		Injury sustained within 24 hrs of presentation	Evidence of intracranial injury on CT (if performed as part of standard clinical care)
8			
9			Significant communication barriers
10			Not fluent in English language
11			
12			Prior medical history of neurological or cognitive impairment
13			
14			
15			
16			
17			
18			
19			
20	<i>Concussed</i>	Diagnosis of maxillofacial injury	LOC > 30mins
21			
22		Clinical features consistent with diagnosis of concussion:	GCS < 13 on presentation
23		- History of direct blow to the head, face, neck or elsewhere on the body with an “impulsive” force transmitted to the head	PTA lasting > 24 hrs (assess at 24 hrs)
24			
25		- History of rapid onset of short-lived impairment of neurologic function that resolves spontaneously	Mechanism of injury due to organised sports activity
26			
27		- No evidence of structural abnormality to the brain seen on standard neuroimaging	
28			
29		- LOC ≤ 30 minutes	
30			
31		- GCS ≥ 13 on presentation	
32			
33		- PTA ≤ 24 hrs	
34			
35			
36			
37			
38			
39			
40			
41	<i>Control</i>	Diagnosis of isolated limb injury	History of TBI
42			
43			Clinical features consistent with diagnosis of concussion according to CISG criteria and ACRM definition
44			
45			
46			Insufficiency, open, femoral or tibia-fibula fracture
47			
48			
49			

LOC (loss of consciousness), GCS (Glasgow Coma Scale), PTA (post traumatic amnesia)

This is an observational study and therefore there will be no study-related interventions in the clinical care of participants. The SCAT5 and ImpACT tools will be used by study investigators to assess

1  
2  
3 participants in addition to their routine clinical care. Salivary sample collection is a non-invasive  
4  
5 procedure.  
6  
7

8 Patients of interest will be compared to patients who had sustained isolated limb trauma as controls.  
9  
10 Patients with isolated limb injury are a suitable control group because they have a comparable burden  
11  
12 of injury and will receive similar management to the concussed group such as operative interventions  
13  
14 and pain management.  
15  
16  
17  
18  
19  
20

### 21 **Patient and public involvement**

  
22  
23

24 A consultation with Patient and Public Involvement and Engagement (PPIE)- the Trauma Advisory  
25  
26 Group (TAG) (previously known as the Accident, Burns and Critical Care group) of the National Institute  
27  
28 for Health Research, Surgical Reconstruction and Microbiology Research Centre (NIHR SRMRC) was  
29  
30 undertaken in June 2018. The TAG consists of around 20 members and are a collective of patients,  
31  
32 family and members of the public with a mixed experience of trauma, burns and critical care. The age  
33  
34 of members ranges from mid-twenties to retirement and the majority have been involved in clinical  
35  
36 research studies.  
37  
38  
39  
40

41 Overall, there was very positive feedback from the group about the study. Members who have been  
42  
43 involved in previous clinical studies stated they liked the study design and expressed interest in joining  
44  
45 the study if they or members of their families were approached. Specifically, the group felt that the  
46  
47 time required to complete study assessments as a participant was reasonable and not too onerous.  
48  
49  
50  
51  
52

### 53 **Feasibility phase and progression criteria**

  
54

55 The feasibility phase (Phase 1) aims to recruit 30 patients within 6 months. Phase 1 will end after 6  
56  
57 months or following the 14-day post-injury time-point of participant number 30—whichever comes  
58  
59  
60

1  
2  
3 sooner. Following the completion of phase 1, the study management group will meet to assess and  
4  
5 attribute a red, amber or green status to the study:  
6  
7

8 **Red:** intractable issues that cannot be remedied; study should not progress to phase 2  
9

10 **Amber:** remediable issues that require attention prior to progressing to phase 2  
11

12  
13 **Green:** no concerning issues that threaten the success of the trial; continue to phase 2 without  
14  
15 substantial amendment (minor amendments may be required).  
16  
17

18  
19 Progression criteria are listed below:  
20  
21

- 22 1. The target recruitment rate is 5 participants per month. If fewer than 70% of the target  
23 recruitment number (21 patients) have been recruited by month 6 of phase 1 without  
24 identifiable and correctable cause it would not be feasible to progress to phase 2.  
25  
26  
27  
28
- 29 2. Following phase 1, if loss to follow up at the 24-48 hrs and 14-day time-points exceeds 30% in  
30 either arm without identifiable and correctable cause, it would not be feasible to progress to  
31 phase 2 without substantial amendments to study design.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## **STUDY PROCEDURE**

A summary of the eligibility criteria and recruitment process is contained in Figure 2.

### **Participant identification**

The research team will approach the potential participant only once eligibility has been confirmed by the treating clinical (either Oral and Maxillofacial or Trauma and Orthopaedics) teams.

### **Screening**

Discussion with the treating clinical team should confirm that the patient will require hospital admission and there is a diagnosis of either maxillofacial injury or isolated limb injury. Any computerised tomography (CT) head scan reports performed as a standard of clinical care must be reviewed to confirm the presence or absence of intracranial injury (according to the eligibility criteria). To confirm a diagnosis consistent with concussion the CISG definition of concussion (1) and the American Congress of Rehabilitation Medicine (ACRM) (20) definition of mTBI must be met.

### **Consent**

Where potential participants fulfil eligibility criteria, they will be approached by a member of the research team who will provide the patient information sheet and clarify any information from the patient/relatives that may prevent recruitment. Wherever possible, informed consent will be obtained from the patient, however due to the nature of concussion, this may not be possible.

The process for obtaining consent in patients lacking capacity is outlined below:

*Patient personal consultee available in hospital*

1  
2  
3 For patients lacking capacity, a personal consultee will be sought. If such a consultee is available in the  
4 hospital, they will be provided with written information about the study and asked if they wish to  
5 provide written agreement prior to enrolment.  
6  
7  
8

9  
10  
11 *Patient personal consultee not available in the hospital*  
12

13 For patients lacking capacity where no personal consultee is available in the hospital, enrolment will  
14 be possible with written agreement from a nominated consultee. If a personal consultee becomes  
15 available, then the study will be discussed with them and written agreement gained for the participant  
16 to continue in the study.  
17  
18  
19  
20

21  
22  
23 *Patients who regain capacity*  
24

25 Where patients regain capacity following either personal or nominated consultee agreement they will  
26 be informed about the study and asked for consent to continue as a participant.  
27  
28

29 If at any time either the personal consultee or participant choose to withhold consent or written  
30 agreement, then the participant will be withdrawn from the study. An agreement with the participant  
31 or personal consultee will be made at this time-point as to whether they give permission for the use  
32 of any data already collected as part of the study or whether they wish for this to be destroyed. If the  
33 data has been analysed, it will not be able to be destroyed and the participant will be informed.  
34  
35  
36  
37  
38  
39  
40

41  
42 *Personal consultee definition*  
43

44 An individual who knows the patient well but is not acting in a professional or paid capacity and  
45 someone whom the person who lacks capacity would trust with important decisions about their  
46 welfare, for example a family member or close friend.  
47  
48  
49  
50

51  
52 *Nominated consultee definition*  
53

54 An independent healthcare professional (IHP) who is prepared to be consulted by the researcher but  
55 has no connection with the research study.  
56  
57  
58  
59  
60



### Baseline and study assessment data

All participants will have a medical history and clinical examination as part of routine standard of care and the following will be recorded in the Case Report Form (CRF). Tables 2 and 3 contain summaries of relevant baseline data and study assessment to be collected at timepoints in the ED, at 24-28hours, 14 days and 6 months.

**Table 2. Baseline data to be collected in the Emergency Department**

<i>Standard of care</i>	Patient demography
	Past medical history (including co-morbidities and medications)
	Injury related events (time of injury, mechanism of injury, subsequent signs/symptoms)
	Neurological status
	Diagnosed injury
	CT head findings (only if performed as standard of care)
<i>Study related data</i>	Medications received
	ImPACT Quick
	SCAT5
	Contact details (telephone and email address)
	Educational level (number of years of education completed)
	Diagnosis of learning disability or Attention Deficit Hyperactivity Disorder
	Level of intoxication (number of units of alcohol consumed as reported by the participant)
	History of concussion or other head injury
<i>Study related sample</i>	Saliva sample

**Table 3. Summary of study assessments at 24-48h, 14 days and 6 months**

<i>24-48 hours</i>	ImPACT
	SCAT5
	Operative interventions
	Neurological status
	Presence or absence of PTA
	CT head findings (only if performed as standard of care)
	Saliva sample
<i>14 days</i>	ImPACT performed remotely (link sent via email)
	SCAT5 symptoms checklist (via telephone)
<i>6 months</i>	SCAT5 symptoms checklist (via telephone)
	Functional data (return to work, return to fitness)

### Qualitative assessment

A qualitative telephone interview will be conducted at 6 months following enrolment. As suggested by the TAG PPIE group, where possible, the interviewer will be the same researcher who has had prior contact with the patient, either in-hospital or via telephone. The format will be of “in-depth semi-structured” interviews on an individual basis. These are interviews organised around a set of predetermined open-ended questions, with other questions generated from subsequent dialogue between interviewer and interviewee. (21) The interviews will be conducted via telephone and recorded for subsequent analysis using NVivo analysis software.

### Collection, storage and testing of saliva samples

1  
2  
3 The samples will be collected in OCR-100saliva collection pots containing a proprietary miRNA  
4 stabilising solution. In these pots samples will be stable at room temperature for 8 weeks and will be  
5 transferred to the laboratory within 1 week of collection to comply with Human Tissue Act  
6 regulations. The samples will be transported to the laboratory at the University of Birmingham  
7 (UoB) and stored in the -80 degrees freezer. miRNA profile will be analysed using standard qPCR  
8 technique. Once the study has been completed all samples will be destroyed.  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18

### 19 **Sample size calculation**

20  
21 As phase 1 is an exploratory cohort study, no formal sample size calculation has been performed.  
22 Following recommendations for pilot studies, 30 patients or more are typically required to obtain  
23 estimates of the parameters needed for sample size estimation. (22, 23) Hence, phase 1 of this study  
24 will aim to recruit 30 patients to estimate the mean and SD of the 7 SCAT5 domain scores and 3  
25 composite ImPACT Quick domain scores in the ED. This will also allow the recruitment and retention  
26 rates to be estimated with 95% confidence interval maximum widths of 27% and 35% respectively.  
27  
28  
29  
30  
31  
32  
33  
34  
35

36 The sample size for phase 2 will be calculated based on the observed distributions of outcome scores  
37 in phase 1.  
38  
39  
40  
41  
42  
43

### 44 **Statistical analysis plan**

45  
46 The data analysis for phase 1 will be descriptive and mainly focus on confidence interval estimation,  
47 with no hypothesis testing performed. Data will be explored to assess the key feasibility aspects of  
48 undertaking a full-scale study on the clinical accuracy of concussion assessment tools in patients with  
49 non-sporting trauma.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Dichotomous feasibility measures, such as the recruitment and retention rates, as well as data  
4 completeness will be reported as numbers and percentages. Where appropriate, these values will be  
5 summarised across patient groups.  
6  
7  
8

9  
10 The phase 1 data will also help inform the selection of the most appropriate primary outcome measure  
11 for the main study and provide data to facilitate estimation of the sample size required for the main  
12 study. Outcome data on concussion assessment tools are collected in ED, at 24-48 hours, 14 days and  
13 6 months post-recruitment. Analysis methods will be chosen according to the data type of the  
14 outcome under investigation, in brief:  
15  
16  
17  
18  
19

- 20  
21  
22 ● *Continuous endpoints (e.g. SCAT5 domain scores)*: These data will be summarised using means  
23 and standard deviations, with differences in means with 95% confidence intervals reported.  
24  
25 Longitudinal plots of the data over time will also be constructed for visual presentation of the  
26 data.  
27  
28  
29  
30  
31  
32 ● *Time to Event endpoints (e.g. time to return to work or recovery)*: The numbers of participants  
33 and percentages experiencing the event will be summarised over time between groups.  
34  
35 Kaplan-Meier curves will be constructed for visual presentation of time-to-event data.  
36  
37  
38  
39  
40  
41

42 The phase 2 data will be used to undertake exploratory analyses of concussion assessment tool  
43 domains adjusted for baseline demographics (age, education level, and gender) and level of self-  
44 reported intoxication.  
45  
46  
47  
48  
49  
50  
51

### 52 **Primary outcome analysis (Phase 1)**

53  
54  
55 The scores in the three ImpACT Quick domains (speed, memory and attention) and 7 SCAT5 domains  
56 (symptoms number, symptom severity, orientation, immediate memory, concentration and balance  
57 errors) will be summarised across the concussed and control groups in ED. These are continuous  
58  
59  
60

1  
2  
3 outcomes, and a linear regression models adjusting for gender, educational level, age, and intoxication  
4  
5 level, will be used to calculate the adjusted mean differences and 95% confidence intervals.  
6  
7 Unadjusted models will be used in the event of the adjusted models failing to converge.  
8  
9

## 10 11 12 **Secondary outcome analysis (Phase 2)** 13

14  
15 Continuous data (e.g. ImPACT and SCAT5 domain scores at specified time-points) will be analysed in  
16  
17 the same way as the primary outcome. The panel of 23 salivary miRNAs will be analysed as continuous  
18  
19 data in the same way as the primary outcome but using a Benjamini-Hochberg procedure to control  
20  
21 the false discovery rate when testing these multiple hypotheses. Time-to-event data (e.g. time to  
22  
23 recovery) will be analysed using the log-rank test with a Cox Proportional Hazard model used to  
24  
25 calculate hazard ratios, if the assumptions of proportionality are met.  
26  
27  
28  
29  
30  
31

## 32 33 **Qualitative analysis** 34

35  
36 Interview data will be audio recorded for analysis using an encrypted audio recorder device. Formal  
37  
38 analysis will be performed using NVivo qualitative data analysis software. Thematic analysis will be  
39  
40 used and some anonymised quotes will be included in the final report. Qualitative data will be  
41  
42 reported according to consolidated criteria for reporting qualitative research (COREQ) guidelines. (24)  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## **ETHICS AND DISSEMINATION**

All study related data collected will be stored on NHS servers in accordance with the 1998 UK Data Protection Act, UoB and University Hospitals Birmingham NHS Foundation Trust data handling and maintenance guidelines. The Trust network has restricted physical access; data are stored under coded file names and the local network has secure password access restricted to researchers involved with the study.

The study investigators intend to submit their study findings for publication in peer reviewed journals, and to disseminate the findings via presentation at academic meetings/conferences. The results will also form part of a doctorate thesis, registered at the University of Birmingham.

Ethical approval was granted in February 2021 (ref 20/WM/0299) by the West Midlands - Coventry & Warwickshire Research Ethics Committee.

## **CONTRIBUTIONS**

ET, JB, AB, VD, DNN, LC contributed to study design. ET, RW, DH, edited study design. ET, MR, DNN, VD, SH, KY contributed to manuscript preparation and editing. All authors agreed on final manuscript edit prior to submission.

## **FUNDING COMPETING INTERESTS**

Prof A Belli and Dr V Di Pietro are members of the research team and shareholders for Marker Diagnostics Ltd, the company providing the funding for the salivary miRNA tests.

Funding for microRNA analysis will be provided by Marker Diagnostics Ltd. Licenses for ImPACT® testing are funded by NIHR SRMRC.

Funding grant awards: not applicable.

## **REFERENCES**

1. McCrory P, Meeuwisse W, Dvorak J, Aubry M, Bailes J, Broglio S, et al. Consensus statement on concussion in sport-the 5(th) international conference on concussion in sport held in Berlin, October 2016. *British journal of sports medicine*. 2017;51(11):838-47.
2. National Clinical Guideline C. National Institute for Health and Clinical Excellence: Guidance. Head Injury: Triage, Assessment, Investigation and Early Management of Head Injury in Children, Young People and Adults. London: National Institute for Health and Care Excellence (UK) Copyright (c) National Clinical Guideline Centre, 2014.; 2014.
3. Rickels E, von Wild K, Wenzlaff P. Head injury in Germany: A population-based prospective study on epidemiology, causes, treatment and outcome of all degrees of head-injury severity in two distinct areas. *Brain Inj*. 2010;24(12):1491-504.
4. Te Ao B, Brown P, Tobias M, Ameratunga S, Barker-Collo S, Theadom A, et al. Cost of traumatic brain injury in New Zealand: evidence from a population-based study. *Neurology*. 2014;83(18):1645-52.
5. Sport concussion assessment tool - 5th edition. *British journal of sports medicine*. 2017;51(11):851-8.
6. Inc IA. ImPACT Applications Products San Diego: ImPACT Applications Inc; 2018 [cited 2018 17th March]. Available from: <https://www.impacttest.com/products/>.
7. Ambros V. The functions of animal microRNAs. *Nature*. 2004;431:350.
8. Di Pietro V, O'Halloran P, Watson CN, Begum G, Acharjee A, Yakoub KM, et al. Unique diagnostic signatures of concussion in the saliva of male athletes: the Study of Concussion in Rugby Union through MicroRNAs (SCRUM). *British journal of sports medicine*. 2021;55(24):1395-404.



- 1  
2  
3 9. Babl FE, Dionisio D, Davenport L, Baylis A, Hearps SJC, Bressan S, et al. Accuracy of Components  
4 of SCAT to Identify Children With Concussion. *Pediatrics*. 2017;140(2).  
5  
6  
7
- 8  
9 10. Bin Zahid A, Hubbard ME, Dammavalam VM, Balser DY, Pierre G, Kim A, et al. Assessment of  
10 acute head injury in an emergency department population using sport concussion assessment tool–  
11 3rd edition. *Applied Neuropsychology:Adult*. 2018;25(2):110-9.  
12  
13  
14
- 15  
16 11. Kruse AJ, Nugent AS, Peterson AR. Using sideline concussion tests in the emergency  
17 department. *Open Access Emergency Medicine*. 2018;10:113-21.  
18  
19  
20
- 21  
22 12. Luoto TM, Silverberg ND, Kataja A, Brander A, Tenovuo O, Öhman J, et al. Sport concussion  
23 assessment tool 2 in a civilian trauma sample with mild traumatic brain injury. *Journal of*  
24 *Neurotrauma*. 2014;31(8):728-38.  
25  
26  
27
- 28  
29 13. Silverberg ND, Luoto TM, Öhman J, Iverson GL. Assessment of mild traumatic brain injury with  
30 the King-Devick Test® in an emergency department sample. *Brain Injury*. 2014;28(12):1590-3.  
31  
32  
33
- 34  
35 14. Alsalaheen B, Stockdale K, Pechumer D, Broglio SP. Validity of the Immediate Post Concussion  
36 Assessment and Cognitive Testing (ImPACT). *Sports Medicine*. 2016;46(10):1487-501.  
37  
38  
39
- 40  
41 15. Nelson LD, Furger RE, Gikas P, Lerner EB, Barr WB, Hammeke TA, et al. Prospective, Head-to-  
42 Head Study of Three Computerized Neurocognitive Assessment Tools Part 2: Utility for Assessment of  
43 Mild Traumatic Brain Injury in Emergency Department Patients. *Journal of the International*  
44 *Neuropsychological Society : JINS*. 2017;23(4):293-303.  
45  
46  
47
- 48  
49 16. Shores EA, Lammel A, Hullick C, Sheedy J, Flynn M, Levick W, et al. The diagnostic accuracy of  
50 the Revised Westmead PTA Scale as an adjunct to the Glasgow Coma Scale in the early identification  
51 of cognitive impairment in patients with mild traumatic brain injury. *Journal of neurology,*  
52 *neurosurgery, and psychiatry*. 2008;79(10):1100-6.  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 17. Toman E BA, Preece A, Yeo D, Belli A, Welbury R, Hammond D. Screening for concussion in the  
4  
5 Emergency Department of a regional Major Trauma Centre; audit and analysis of 500 patients. 2018.  
6  
7
- 8  
9 18. Myers K, Kondamudi N, Hartsgrove C, Weingart A. 217 Making the Diagnosis of Concussion in  
10  
11 the Emergency Department: Are We Hitting the Mark? *Annals of Emergency Medicine*. 2017;70(4,  
12  
13 Supplement):S87.  
14  
15
- 16  
17 19. Hammond D, Welbury R, Sammons G, Toman E, Harland M, Rice S. How do oral and  
18  
19 maxillofacial surgeons manage concussion? *The British journal of oral & maxillofacial surgery*.  
20  
21 2018;56(2):134-8.  
22  
23
- 24  
25 20. Definition of mild traumatic brain injury. *The Journal of Head Trauma Rehabilitation*.  
26  
27 1993;8(3):86-7.  
28  
29
- 30  
31 21. Diccico-Bloom B, Crabtree BF. The qualitative research interview. *Medical education*.  
32  
33 2006;40(4):314-21.  
34  
35
- 36  
37 22. Lancaster GA, Dodd S, Williamson PR. Design and analysis of pilot studies: recommendations  
38  
39 for good practice. *Journal of evaluation in clinical practice*. 2004;10(2):307-12.  
40  
41
- 42  
43 23. Browne RH. On the use of a pilot sample for sample size determination. *Statistics in medicine*.  
44  
45 1995;14(17):1933-40.  
46  
47
- 48  
49 24. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ):  
50  
51 a 32-item checklist for interviews and focus groups. *International Journal for Quality in Health Care*.  
52  
53 2007;19(6):349-57.  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **FIGURE LEGENDS**  
4  
5  
6

7 **Figure 1. CISG definition of concussion**  
8  
9

10 **Figure 2. Study protocol flowsheet**  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 
- History of direct blow to the head, face, neck or elsewhere on the body with an “impulsive” force transmitted to the head
  - History of rapid onset of short-lived impairment of neurologic function that resolves spontaneously
  - No evidence of structural abnormality to the brain seen on standard neuroimaging
  - LOC for no longer than 30 minutes
  - GCS of 13 or higher on presentation
  - PTA for no longer than 24 hrs
- 

CISG: Concussion in Sport Group; LOC: loss of consciousness; GCS: Glasgow Coma Scale; PTA: post-traumatic amnesia

Figure 1. CISG definition of concussion

221x109mm (192 x 192 DPI)




Figure 2. Study protocol flowsheet

86x101mm (192 x 192 DPI)

# BMJ Open

**The CONcussion in non-aThletes; Assessment of CognITion and Symptomatology (CONTACTS) study protocol: An exploratory cohort study investigating the utility of sports concussion assessment tools and salivary micro-RNAs to diagnose concussion in NHS patients**

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-062030.R1
Article Type:	Protocol
Date Submitted by the Author:	21-Jul-2022
Complete List of Authors:	Toman, Emma; University of Birmingham; University Hospitals Birmingham NHS Foundation Trust Riley, Max; University of Birmingham, Medical School Hodgson, Sam; University of Birmingham, Medical School Yakoub, Kamal; University Hospitals Birmingham NHS Foundation Trust, NIHR SRMRC Cooper, Lauren; University Hospitals Birmingham NHS Foundation Trust Bishop, Jon; University of Birmingham, Medical Statistician Naumann, David; Royal Centre for Defence Medicine; University Hospitals Birmingham NHS Foundation Trust, General Surgery Welbury, Richard; University of Central Lancashire, School of Dentistry Hammond, Douglas; Blackpool Teaching Hospitals NHS Foundation Trust, Department of Oral and Maxillofacial Surgery Di Pietro, Valentina; University of Birmingham, Institute of Inflammation and Ageing Belli, Antonio; NIHR Surgical Reconstruction and Microbiology Research Centre, Neurosurgery; University of Birmingham, School of Clinical and Experimental Medicine
<b>Primary Subject Heading</b>:	Emergency medicine
Secondary Subject Heading:	Surgery
Keywords:	ACCIDENT & EMERGENCY MEDICINE, Neurological injury < NEUROLOGY, NEUROSURGERY, TRAUMA MANAGEMENT

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6  
7  
8  
9

# The CONcussion in non-aThletes; Assessment of CogniTion and Symptomatology (CONTACTS) study protocol: An exploratory cohort study investigating the utility of sports concussion assessment tools and salivary micro-RNAs to diagnose concussion in NHS patients

10  
11  
12  
13  
14  
15

Emma Toman,<sup>1,2,3</sup> Max Riley,<sup>4</sup> Sam Hodgson,<sup>4</sup> Kamal M Yakoub,<sup>2</sup> Lauren Cooper,<sup>2</sup> Jon Bishop,<sup>2,5</sup> David N Naumann,<sup>6,7</sup> Richard Welbury,<sup>8</sup> Douglas Hammond,<sup>9</sup> Valentina Di Pietro,<sup>1</sup> Antonio Belli<sup>1,2,3</sup>

16  
17

*Corresponding author:*

18  
19

*Ms. Emma Toman*

20  
21  
22  
23  
24

*4<sup>th</sup> Floor, NIHR Surgical Reconstruction and Microbiology Research Centre, Institute of Translational Medicine, Heritage Building, Mindelsohn Way. Edgbaston, Birmingham, B15 2WB  
ekt635@student.bham.ac.uk*

- 25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47
1. Neurotrauma and Ophthalmology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK
  2. NIHR Surgical Reconstruction and Microbiology Research Centre, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
  3. Department of Neurosurgery, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
  4. College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK
  5. Institute of Applied Health Research, University of Birmingham, Birmingham, UK
  6. Royal Centre for Defence Medicine, Birmingham, UK
  7. Department of General Surgery, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
  8. School of Dentistry, University of Central Lancashire, Preston, UK
  9. Department of Oral and Maxillofacial Surgery, Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool, UK

48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Word count: 3338**

## **ABSTRACT**

### **Introduction:**

Concussion is a complex pathophysiological process with a wide range of non-specific signs and symptoms. There are currently no objective diagnostic tests to identify concussion, and diagnosis relies solely on history and examination. Recent research has identified a unique panel of micro-RNAs (miRNAs) that distinguish between concussed and non-concussed rugby players. This study aims to assess the diagnostic utility of salivary miRNAs in concussion for a sample of UK National Health Service (NHS) patients, and whether well-established sports-related concussion (SRC) assessment tools may be translated into the Emergency Department (ED).

### **Methods and analysis:**

CONTACTS is a single-centre, prospective, two-phase cohort study. The concussed cohort will consist of participants with maxillofacial trauma and concurrent concussion. The control cohort will consist of participants with isolated limb trauma and no evidence of concussion. Participants will be recruited in the ED and saliva samples will be taken to identify the presence of miRNAs. The SRC assessments being investigated include the Sports Concussion Assessment Test version 5 (SCAT5), the Immediate Post-Concussive Assessment and Cognitive Test (ImPACT), and the ImPACT Quick. Follow-up will be at 24-48 hours in-hospital and remotely via telephone and email at 14 days and 6 months.

### **Ethics and dissemination:**

Ethical approval was granted in February 2021 by the West Midlands - Coventry & Warwickshire Research Ethics Committee (ref 20/WM/0299). The investigators intend to submit their study findings for publication in peer-reviewed journals and to disseminate study findings via presentation at academic meetings. The results will also form part of a doctorate thesis, registered at the University of Birmingham.



## **STRENGTHS AND LIMITATIONS OF THIS STUDY**

- Incorporated feasibility phase to ensure the study is correctly powered
- Pragmatic design that allows assessment of potential clinical utility
- Traditionally excluded groups (older patients, those suffering from mental health conditions and concurrent intoxication) are to be included, to improve the translation into clinical practice
- COVID may limit the amount of time patients are in ED and so the design may need to be adapted
- Those with premorbid neurological or cognitive issues were unable to be included in this study which may limit the translation of any findings into clinical practice
- Patients discharged home from ED are not included in the study design

## **INTRODUCTION**

### **Background and previous literature:**

Concussion is defined as “a complex pathophysiological process affecting the brain, induced by traumatic biomechanical forces”. (1) Signs and symptoms are nonspecific and are largely categorised into physical, cognitive, behavioural, and sleep. The Concussion in Sport Group (CISG) and the American Congress of Rehabilitation Medicine (ACRM) provide clear definitions of concussion and mild traumatic brain injury (mTBI) with clinical criteria that are summarised in Figure 1. (1, 2)

Each year 1.4 million people present to the Emergency Department (ED) in England and Wales with traumatic brain injury (TBI). (3) Since 90% of TBI cases are classified as mild in severity (4) and have an estimated lifetime cost of \$5,299, (5) concussion represents an extensive financial burden and is a substantial public health concern.

Diagnosis remains the main stumbling block in the management of concussion. There is currently no objective diagnostic test in clinical practice to identify the condition, and therefore diagnosis relies solely on history and examination. This poses difficulty where there are no witnesses to the event or the patient suffers from existing cognitive, neurological, or psychiatric disorders. The CISG has suggested that no single investigation should be used to diagnose concussion. Instead, several techniques should be used in combination with clinical judgement. (1) Two such widely accepted tools include the paper-based Sports Concussion Assessment Tool 5<sup>th</sup> edition (SCAT5) (6) and the computerised neurocognitive Immediate Post-Concussive Assessment and Cognitive Test (ImPACT). (7) Combined, these tools assess a wide variety of domains that can be affected by concussion including physical signs, symptoms, memory, concentration, balance, gait, reaction time, and attention.

1  
2  
3 Selection bias is the most common drawback of applying existing evidence to non-athletes. Older  
4  
5 people, those under the influence of alcohol or drugs, and patients with existing cognitive,  
6  
7 neurological or psychiatric conditions have traditionally been excluded from previous studies. This  
8  
9 means that any prior findings may not apply to the overall UK National Health Service (NHS) population  
10  
11 presenting to services with concussion.  
12  
13

14  
15 In addition to diagnosis, the follow-up of concussed patients within the NHS needs to be addressed.  
16  
17 The main difficulty in following up such individuals is the sheer number of patients suffering  
18  
19 concussions. This would make face-to-face clinic follow-up of all patients a huge logistical challenge  
20  
21 and costly to an already cash-strapped NHS. Innovative methods of follow-up should be researched  
22  
23 and would likely involve remote reviews, as have become more common since the COVID-19  
24  
25 pandemic.  
26  
27  
28  
29  
30  
31  
32

### 33 **Salivary microRNAs (miRNAs)**

34  
35

36 Salivary miRNAs have recently been identified as the most promising biomarker in the identification  
37  
38 of concussion in sport. miRNAs are non-coding fragments of RNA that play an important role in gene  
39  
40 expression. (8) The most significant study so far in the investigation of salivary miRNA was the Study  
41  
42 of Concussion in Rugby Union through MicroRNAs; the “SCRUM study”, results of which were  
43  
44 published in 2021. This study found that a panel of 14 miRNAs successfully identified concussed rugby  
45  
46 players from those with a negative concussion assessment, non-injured controls, and musculoskeletal  
47  
48 injured controls. The miRNA panel was able to differentiate concussed participants from the other  
49  
50 groups immediately after the game (AUC 0.91, 95% CI 0.81 to 1) and 36–48 hours later (AUC 0.94,  
51  
52 95% CI 0.86 to 1). (9) These findings have significant implications for use in professional sports.  
53  
54 Therefore it may be of use in non-athletes to detect concussion in the ED. Salivary miRNAs are worthy  
55  
56  
57  
58  
59  
60

1  
2  
3 of further investigation in the non-athlete setting where there are a far greater variation in age, and  
4  
5 physical and cognitive baseline characteristics of patients presenting with a head injury.  
6  
7  
8  
9

### 10 11 **Sports Concussion Assessment Tool 5<sup>th</sup> edition (SCAT5)** 12

13  
14 The SCAT5 is the most recent version of the SCAT, based on a systematic review of recent research  
15 and expert panel input as part of the 5th International Consensus Conference on Concussion in Sport  
16 held in Berlin in 2016. (1) The SCAT5 is a widely used tool used in the assessment of sports-related  
17 concussion in patients 13 years or older and should take no less than 10 minutes to perform. The  
18 diagnostic utility of the SCAT decreases after 3–5 days and has limited utility in tracking the recovery  
19 of patients. (6) The assessment should be conducted by healthcare professionals only and is not  
20 designed to be a standalone tool in the diagnosis of concussion.  
21  
22  
23  
24  
25  
26  
27  
28  
29

30  
31 Very few studies using SCAT in non-athlete populations have been published most data coming from  
32 adolescent athletes. A shared finding across non-athlete studies is that symptom number and severity  
33 seem to provide the most diagnostic accuracy for discriminating between concussed and control  
34 patients. (10-14) The balance assessment is not well tolerated in non-athletes (12) and poses obvious  
35 problems where the control sample have suffered limb injury. Very few studies have reported  
36 individual elements of the SCAT assessment, with the majority combining all non-symptom sections  
37 of the test to provide a Standardised Assessment of Concussion (SAC) score.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

### 51 **Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT)** 52

53  
54 The ImPACT is a computer-based neurocognitive assessment widely used of professional sports. (7)  
55 The ImPACT should be administered by a healthcare professional and is validated for patients aged  
56 12-59 years. The test should take 20-25 minutes to administer and considers several different  
57  
58  
59  
60

assessment domains. As with the SCAT5, the ImPACT is not designed to be used as a standalone diagnostic tool. The ImPACT provides composite domain scores for verbal memory, visual memory, reaction time, processing speed and impulse control. Details of specific tests and how composite scores are calculated are included in Table 1.

**Table 1. ImPACT composite score calculations**

ImPACT composite score	Calculation
Verbal memory	Average of these scores: <ul style="list-style-type: none"> <li>• Word Memory total percent correct (immediate + delay) / 2</li> <li>• Symbol Match (hidden symbols)/9*100</li> <li>• Three letters Total letters correct</li> </ul>
Visual memory	Average of the following scores: <ul style="list-style-type: none"> <li>• X's and O's-total correct (interference) total/4</li> <li>• Design memory-total percent correct (immediate + delay) / 2</li> </ul>
Reaction time	Average of these scores: <ul style="list-style-type: none"> <li>• X's and O's average correct RT</li> <li>• Symbol Match average correct RT/3</li> <li>• Colour Match average correct RT</li> </ul>
Processing speed	Average of the following scores: <ul style="list-style-type: none"> <li>• X's and O's-total correct (interference) total/4</li> <li>• Three letters-average counted correctly*3</li> </ul>
Impulse control	Sum of the following scores: <ul style="list-style-type: none"> <li>• X's and O's-total incorrect –interference</li> <li>• Colour match total commissions</li> </ul>

This requires a pre-injury assessment to which post-concussion scores are compared. The program calculates a reliable change index (RCI) score and where this exceeds the expected range in variation, identifies it as abnormal. (7) The ImPACT Quick programme was designed for use at the pitch side and

1  
2  
3 to aid in removal-from-play decisions. Rather than relying on a pre-test score to compare, the results  
4  
5 are presented as percentile scores from a large representative sample of individuals with no history  
6  
7 of concussion.  
8  
9

10  
11 A recent literature review examining the validity of the ImPACT revealed that although the tool  
12  
13 demonstrated sound convergent validity, research describing discriminant validity and diagnostic  
14  
15 accuracy was either inconclusive or scanty. (15) This provides support for further studies in this area.  
16  
17 Very few of the studies included in the review concerned the use of the ImPACT in non-athlete  
18  
19 populations and three of the sixty-nine studies analysed the use of the ImPACT in concussed versus  
20  
21 controls suffering orthopaedic injuries.  
22  
23

24  
25 Non-athlete studies using the ImPACT have produced conflicting results. A 2017 American study  
26  
27 recruited 94 concussed patients and 80 matched-trauma controls from ED and performed the ImPACT  
28  
29 within 72 hours of injury, 15 days, and 45 days. (16) No significant difference in composite scores were  
30  
31 found between groups at any of the time points. By comparison, an Australian study assessing 79  
32  
33 concussed patients to 86 trauma control patients in the ED found significant differences in all 5  
34  
35 composite domain scores. (17)  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51

## 52 **RATIONALE**

53  
54 Previous work suggests that concussion remains underdiagnosed in the ED (18, 19) and patients may  
55  
56 not be followed up adequately in clinical practice. (20) This may reflect the complex nature of  
57  
58 diagnosing and monitoring concussion but may also demonstrate the lack of NHS resources allocated  
59  
60

1  
2  
3 towards concussion care. Additional common barriers to screening for concussion in NHS patients  
4  
5 such as intoxication and dementia complicate recognition and diagnosis further. (18) It is important  
6  
7 therefore to assess whether well-established SRC assessment tools may be translated into the non-  
8  
9 sporting population of the NHS. A longer-term qualitative review of the tools would add depth to  
10  
11 existing data and also indicate the willingness of non-athletes to engage in these tests using telephone  
12  
13 and email reviews.  
14  
15

16  
17 Currently, the National Institute for Health and Care Excellence (NICE) guidelines concerning head  
18  
19 injury focus on appropriate triage and acute management. No guidelines exist regarding follow-up or  
20  
21 referral of patients with ongoing symptoms. More innovative ways of monitoring recovery and  
22  
23 symptoms in such patients need to be developed, ideally remotely. A concussion assessment that is  
24  
25 clinically accurate and that patients can—and want to—perform at home could revolutionise the  
26  
27 possibilities in which secondary care clinicians could manage these patients.  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## **METHODS AND ANALYSIS**

### **Study Design**

CONTACTS is a prospective cohort study investigating the use of sports concussion assessment tools and the diagnostic utility of salivary miRNAs in concussed versus control adult participants following non-sporting maxillofacial trauma. It will commence with a phase 1, feasibility study followed by a phase 2, substantive study if progression criteria are met. Both phases will take place at the Queen Elizabeth Hospital Birmingham (QEHB) as a single-centre study. Participants will be followed up for 6 months post recruitment. Phase 1 commenced on 21/07/2021 and the planned end date for recruitment to all study phases is 01/10/2023.

Patients of interest are adult patients who require hospital admission following non-sporting isolated maxillofacial trauma. Recruiting patients with maxillofacial trauma to the concussion arm ensures that there is objective evidence of head injury having occurred. This also provides a sample of patients who require admission to hospital, whereas isolated concussion does not usually require admission to hospital.

### **Eligibility Criteria**

For patients with isolated concussion, the standard clinical care would be discharge from the ED with a responsible adult and suitable head injury advice. To optimise the rate of follow-up of participants, only patients requiring admission will be recruited. To ensure that all participants in the concussion arm have suffered an impact to the head, face, or neck (as required for concussion diagnosis according to CISG definition), only patients with maxillofacial injury will be recruited. Brain imaging is not an inclusion criterion as not all patients suffering from concussion require CT scanning (3) and we wish to reflect clinical practice in this pragmatic study design. The control arm will consist of participants having suffered an isolated limb injury. Inclusion and exclusion criteria are summarised in table 2.



**Table 2. Summary of eligibility criteria for the CONTACTS study**

<b>Cohort</b>	<b>Inclusion</b>	<b>Exclusion</b>	
<i>Both</i>	≥16 years old	Police custody	
	Requires admission to QEHB	Prisoner	
	Injury sustained within 24 hrs of presentation	Evidence of intracranial injury on CT (if performed as part of standard clinical care)	
		Significant communication barriers	
		Not fluent in the English language	
		Prior medical history of neurological or cognitive impairment	
<i>Concussed</i>	Diagnosis of maxillofacial injury	LOC > 30mins	
	Clinical features consistent with a diagnosis of concussion:	GCS < 13 on presentation	
	- History of direct blow to the head, face, neck, or elsewhere on the body with an “impulsive” force transmitted to the head	PTA lasting > 24 hrs (assess at 24 hrs)	
	- History of rapid onset of short-lived impairment of neurologic function that resolves spontaneously	Mechanism of injury due to organised sports activity	
	- No evidence of structural abnormality to the brain seen on standard neuroimaging		
	- LOC ≤ 30 minutes		
	- GCS ≥ 13 on presentation		
	- PTA ≤ 24 hrs		
	<i>Control</i>	Diagnosis of isolated limb injury	History of TBI
			Clinical features consistent with a diagnosis of concussion according to CISG criteria and ACRM definition
		Insufficiency, open, femoral, or tibia-fibula fracture	

LOC (loss of consciousness), GCS (Glasgow Coma Scale), PTA (post-traumatic amnesia)

1  
2  
3 This is an observational study and therefore there will be no study-related interventions in the clinical  
4 care of participants. The SCAT5 and ImpACT tools will be used by study investigators to assess  
5 participants in addition to their routine clinical care. Salivary sample collection is a non-invasive  
6 procedure.  
7  
8  
9  
10  
11  
12

13 Concussed participants will be compared to participants who had sustained isolated limb trauma as  
14 controls. Patients with isolated limb injuries are a suitable control group because they have similar  
15 Abbreviated Injury Scale (AIS) severity codes to concussion and facial injuries. (21) Isolated lower limb  
16 injuries requiring admission will also receive similar management to the concussed group such as  
17 operative interventions and pain management.  
18  
19  
20  
21  
22  
23  
24  
25  
26

### 27 **Patient and public involvement**

28  
29  
30 A consultation with Patient and Public Involvement and Engagement (PPIE)- the Trauma Advisory  
31 Group (TAG) (previously known as the Accident, Burns, and Critical Care group) of the National  
32 Institute for Health Research, Surgical Reconstruction and Microbiology Research Centre (NIHR  
33 SRMRC) was undertaken in June 2018. The TAG consists of around 20 members and is a collective of  
34 patients, family, and members of the public with a mixed experience of trauma, burns, and critical  
35 care. The age of members ranges from mid-twenties to retirement and the majority have been  
36 involved in clinical research studies.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

47 Overall, there was very positive feedback from the group about the study. Members who have been  
48 involved in previous clinical studies stated they liked the study design and expressed interest in joining  
49 the study if they or members of their families were approached. Specifically, the group felt that the  
50 time required to complete study assessments as a participant was reasonable and not too onerous.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### **Feasibility phase and progression criteria**

1  
2  
3 The feasibility phase (Phase 1) aims to recruit 30 patients within 6 months. Phase 1 will end after 6  
4 months or following the 14-day post-injury time-point of participant number 30—whichever comes  
5  
6 months or following the 14-day post-injury time-point of participant number 30—whichever comes  
7  
8 sooner. Following the completion of phase 1, the study management group will meet to assess and  
9  
10 attribute a red, amber, or green status to the study:  
11

12  
13 **Red:** intractable issues that cannot be remedied; study should not progress to phase 2  
14

15 **Amber:** remediable issues that require attention before progressing to phase 2  
16

17 **Green:** no concerning issues that threaten the success of the trial; continue to phase 2 without  
18  
19 substantial amendment (minor amendments may be required).  
20  
21

22  
23  
24 Progression criteria are listed below:  
25

- 26  
27 1. The target recruitment rate is 5 participants per month. If fewer than 70% of the target  
28  
29 recruitment number (21 patients) have been recruited by month 6 of phase 1 without  
30  
31 identifiable and correctable cause it would not be feasible to progress to phase 2.  
32  
33
- 34 2. Following phase 1, if the loss to follow up at the 24-48 hrs and 14-day time-points exceed 30%  
35  
36 in either arm without identifiable and correctable cause, it would not be feasible to progress  
37  
38 to phase 2 without substantial amendments to study design.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## **STUDY PROCEDURE**

A summary of the eligibility criteria and recruitment process is contained in Figure 2.

### **Participant identification**

The research team will approach the potential participant only once eligibility has been confirmed by the treating clinical (either Oral and Maxillofacial or Trauma and Orthopaedics) teams.

### **Screening**

Discussion with the treating clinical team should confirm that the patient will require hospital admission and there is a diagnosis of either maxillofacial injury or isolated limb injury. Any computerised tomography (CT) head scan reports performed as a standard of clinical care must be reviewed to confirm the presence or absence of intracranial injury (according to the eligibility criteria). To confirm a diagnosis consistent with a concussion the CISG definition of concussion (1) and the American Congress of Rehabilitation Medicine (ACRM) (2) definition of mTBI must be met.

### **Consent**

When potential participants fulfil eligibility criteria, they will be approached by a member of the research team who will provide the patient information sheet and clarify any information from the patient/relatives that may prevent recruitment. Wherever possible, informed consent will be obtained from the patient,, however due to the nature of concussion, this may not be possible.

The process for obtaining consent in patients lacking capacity is outlined below:

*Patient personal consultee available in hospital*

1  
2  
3 For patients lacking capacity, a personal consultee will be sought. If such a consultee is available in the  
4 hospital, they will be provided with written information about the study and asked if they wish to  
5 provide written agreement prior to enrolment.  
6  
7  
8

9  
10  
11 *Patient personal consultee not available in the hospital*  
12

13 For patients lacking capacity where no personal consultee is available in the hospital, enrolment will  
14 be possible with written agreement from a nominated consultee. If a personal consultee becomes  
15 available, then the study will be discussed with them, and written agreement gained for the  
16 participant to continue in the study.  
17  
18  
19  
20

21  
22  
23 *Patients who regain capacity*  
24

25 Where patients regain capacity following either personal or nominated consultee agreement they will  
26 be informed about the study and asked for consent to continue as a participant.  
27  
28

29 If at any time either the personal consultee or participant choose to withhold consent or written  
30 agreement, then the participant will be withdrawn from the study. An agreement with the participant  
31 or personal consultee will be made at this time-point as to whether they give permission for the use  
32 of any data already collected as part of the study or whether they wish for this to be destroyed. If the  
33 data have been analysed, it will not be able to be destroyed and the participant will be informed.  
34  
35  
36  
37  
38  
39  
40

41  
42 *Personal consultee definition*  
43

44 An individual who knows the patient well but is not acting in a professional or paid capacity and  
45 someone whom the person who lacks capacity would trust with important decisions about their  
46 welfare, for example a family member or close friend.  
47  
48  
49  
50

51  
52 *Nominated consultee definition*  
53

54 An independent healthcare professional (IHP) who is prepared to be consulted by the researcher but  
55 has no connection with the research study.  
56  
57  
58  
59  
60

### Baseline and study assessment data

All participants will have a medical history and clinical examination as part of routine standard of care and the following will be recorded in the Case Report Form (CRF). Tables 3 and 4 contain summaries of relevant baseline data and study assessment to be collected at timepoints in the ED, at 24-28hours, 14 days and 6 months.

No specific study “test conditions” will be imposed during the study assessments to continue the pragmatic nature of the study. Study assessments will be conducted in the real-life clinical environment to provide a true reflection of the translatability of any study results.

**Table 3. Baseline data to be collected in the Emergency Department**

<i>Standard of care</i>	Patient demography
	Past medical history (including co-morbidities and medications)
	Injury related events (time of injury, mechanism of injury, subsequent signs/symptoms)
	Neurological status
	Diagnosed injury
	CT head findings (only if performed as standard of care)
	Medications received
<i>Study related data</i>	ImPACT Quick
	SCAT5
	Contact details (telephone and email address)
	Educational level (number of years of education completed)
	Diagnosis of learning disability or Attention Deficit Hyperactivity Disorder
	Level of intoxication (number of units of alcohol consumed as reported by the participant)

	History of concussion or other head injury
<i>Study related sample</i>	Saliva sample

**Table 4. Summary of study assessments at 24-48h, 14 days and 6 months**

<i>24-48 hours</i>	ImPACT
	SCAT5
	Operative interventions
	Neurological status
	Presence or absence of PTA
	CT head findings (only if performed as standard of care)
	Saliva sample
<i>14 days</i>	ImPACT performed remotely (link sent via email)
	SCAT5 symptoms checklist (via telephone)
<i>6 months</i>	SCAT5 symptoms checklist (via telephone)
	Functional data (return to work, return to fitness)

### Qualitative assessment

A qualitative telephone interview will be conducted at 6 months following enrolment. As suggested by the TAG PPIE group, where possible, the interviewer will be the same researcher who has had prior contact with the patient, either in-hospital or via telephone. The format will be of “in-depth semi-structured” interviews on an individual basis. These are interviews organised around a set of predetermined open-ended questions, with other questions generated from subsequent dialogue between interviewer and interviewee. (22) The interviews will be conducted via telephone and recorded for subsequent analysis using NVivo analysis software.

### **Collection, storage and testing of saliva samples**

The samples will be collected in OCR-100 saliva collection pots containing a proprietary miRNA stabilising solution. Saliva is collected using a standardised technique where the user gently rubs the sponge swab along the lower gums ten times on either side of the mouth. In these pots samples will be stable at room temperature for 8 weeks and will be transferred to the laboratory within 1 week of collection to comply with Human Tissue Act regulations. The samples will be transported to the laboratory at the University of Birmingham (UoB) and stored in the -80 degrees freezer. miRNA profile will be analysed using standard qPCR technique. Once the study has been completed all samples will be destroyed.

### **Sample size calculation**

As phase 1 is an exploratory cohort study, no formal sample size calculation has been performed. Following recommendations for pilot studies, 30 patients or more are typically required to obtain estimates of the parameters needed for sample size estimation. (23, 24) Hence, phase 1 of this study will aim to recruit 30 patients to estimate the mean and SD of the 7 SCAT5 domain scores and 3 composite ImPACT Quick domain scores in the ED. This will also allow the recruitment and retention rates to be estimated with 95% confidence interval maximum widths of 27% and 35% respectively.

The sample size for phase 2 will be calculated based on the observed distributions of outcome scores in phase 1.

### **Statistical analysis plan**

The data analysis for phase 1 will be descriptive and mainly focus on confidence interval estimation, with no hypothesis testing performed. Data will be explored to assess the key feasibility aspects of



1  
2  
3 undertaking a full-scale study on the clinical accuracy of concussion assessment tools in patients with  
4  
5 non-sporting trauma.  
6  
7

8 Dichotomous feasibility measures, such as the recruitment and retention rates, as well as data  
9  
10 completeness will be reported as numbers and percentages. Where appropriate, these values will be  
11  
12 summarised across patient groups.  
13  
14

15 Phase 1 data will inform the selection of the primary outcomes for the main study and provide  
16  
17 estimates for sample size calculations. Outcome data on concussion assessment tools are collected in  
18  
19 ED, at 24-48 hours, 14 days and 6 months post-recruitment. Analysis methods will be chosen according  
20  
21 to the data type of the outcome under investigation, in brief:  
22  
23

- 24  
25 ● *Continuous endpoints (e.g., SCAT5 domain scores)*: These data will be summarised using  
26  
27 means and standard deviations, with differences in means with 95% confidence intervals  
28  
29 reported. Longitudinal plots of the data over time will also be constructed for visual  
30  
31 presentation of the data.  
32  
33
- 34  
35 ● *Time to Event endpoints (e.g., time to return to work or recovery)*: The numbers of participants  
36  
37 and percentages experiencing the event will be summarised over time between groups.  
38  
39 Kaplan-Meier curves will be constructed for visual presentation of time-to-event data.  
40  
41  
42  
43  
44

45 The phase 2 data will be used to undertake exploratory analyses of concussion assessment tool  
46  
47 domains adjusted for baseline demographics (age, education level, and gender) and level of self-  
48  
49 reported intoxication.  
50  
51

## 52 53 54 55 **Primary outcome analysis (Phase 1)** 56 57 58 59 60

1  
2  
3 The scores in the three ImpACT Quick domains (speed, memory and attention) and 7 SCAT5 domains  
4 (symptoms number, symptom severity, orientation, immediate memory, concentration and balance  
5 errors) will be summarised across the concussed and control groups in ED. These are continuous  
6 outcomes, and a linear regression model adjusting for gender, educational level, age, and intoxication  
7 level, will be used to calculate the adjusted mean differences and 95% confidence intervals.  
8 Unadjusted models will be used in the event of the adjusted models failing to converge.  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18

### 19 **Secondary outcome analysis (Phase 2)**

20  
21  
22 Continuous data (e.g., ImpACT and SCAT5 domain scores at specified time-points) will be analysed in  
23 the same way as the primary outcome. The panel of 23 salivary miRNAs will be analysed as continuous  
24 data in the same way as the primary outcome but using a Benjamin-Hochberg procedure to control  
25 the false discovery rate when testing these multiple hypotheses. Time-to-event data (e.g., time to  
26 recovery) will be analysed using the log-rank test with a Cox Proportional Hazard model used to  
27 calculate hazard ratios, if the assumptions of proportionality are met.  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38

### 39 **Qualitative analysis**

40  
41  
42 Interview data will be audio recorded for analysis using an encrypted audio recorder device. Formal  
43 analysis will be performed using NVivo qualitative data analysis software. Thematic analysis will be  
44 used, and some anonymised quotes will be included in the final report. Qualitative data will be  
45 reported according to consolidated criteria for reporting qualitative research (COREQ) guidelines. (25)  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## **ETHICS AND DISSEMINATION**

All study related data collected will be stored on NHS servers in accordance with the 1998 UK Data Protection Act, UoB and University Hospitals Birmingham NHS Foundation Trust data handling and maintenance guidelines. The Trust network has restricted physical access; data are stored under coded file names and the local network has secure password access restricted to researchers involved with the study.

The study investigators intend to submit their study findings for publication in peer reviewed journals, and to disseminate the findings via presentation at academic meetings/conferences. The results will also form part of a doctorate thesis, registered at the University of Birmingham.

Ethical approval was granted in February 2021 (ref 20/WM/0299) by the West Midlands - Coventry & Warwickshire Research Ethics Committee.

## **CONTRIBUTORSHIP**

ET, JB, AB, VD, DNN, LC contributed to study design. ET, RW, DH, edited study design. ET, MR, DNN, VD, SH, KY contributed to manuscript preparation and editing. All authors agreed on final manuscript edit prior to submission.

## **FUNDING STATEMENT**

Funding for microRNA analysis will be provided by Marker Diagnostics Ltd. Licenses for ImPACT® testing are funded by NIHR SRMRC.

Funding grant awards: not applicable.

## **COMPETING OF INTERESTS**

Prof A Belli and Dr V Di Pietro are members of the research team and shareholders for Marker Diagnostics Ltd, the company providing the funding for the salivary miRNA tests.

## **REFERENCES**

1. McCrory P, Meeuwisse W, Dvorak J, Aubry M, Bailes J, Broglio S, et al. Consensus statement on concussion in sport-the 5(th) international conference on concussion in sport held in Berlin, October 2016. *British journal of sports medicine*. 2017;51(11):838-47.
2. Definition of mild traumatic brain injury. *The Journal of Head Trauma Rehabilitation*. 1993;8(3):86-7.
3. National Clinical Guideline C. National Institute for Health and Clinical Excellence: Guidance. Head Injury: Triage, Assessment, Investigation and Early Management of Head Injury in Children, Young People and Adults. London: National Institute for Health and Care Excellence (UK) Copyright (c) National Clinical Guideline Centre, 2014.; 2014.
4. Rickels E, von Wild K, Wenzlaff P. Head injury in Germany: A population-based prospective study on epidemiology, causes, treatment and outcome of all degrees of head-injury severity in two distinct areas. *Brain Inj*. 2010;24(12):1491-504.
5. Te Ao B, Brown P, Tobias M, Ameratunga S, Barker-Collo S, Theadom A, et al. Cost of traumatic brain injury in New Zealand: evidence from a population-based study. *Neurology*. 2014;83(18):1645-52.
6. Sport concussion assessment tool - 5th edition. *British journal of sports medicine*. 2017;51(11):851-8.
7. Inc IA. ImPACT Applications Products San Diego: ImPACT Applications Inc; 2018 [cited 2018 17th March]. Available from: <https://www.impacttest.com/products/>.
8. Ambros V. The functions of animal microRNAs. *Nature*. 2004;431:350.
9. Di Pietro V, O'Halloran P, Watson CN, Begum G, Acharjee A, Yakoub KM, et al. Unique diagnostic signatures of concussion in the saliva of male athletes: the Study of Concussion in Rugby Union through MicroRNAs (SCRUM). *British journal of sports medicine*. 2021;55(24):1395-404.
10. Babl FE, Dionisio D, Davenport L, Baylis A, Hearps SJC, Bressan S, et al. Accuracy of Components of SCAT to Identify Children With Concussion. *Pediatrics*. 2017;140(2).

- 1  
2  
3 11. Bin Zahid A, Hubbard ME, Dammavalam VM, Balsler DY, Pierre G, Kim A, et al. Assessment of  
4 acute head injury in an emergency department population using sport concussion assessment tool–  
5 3rd edition. *Applied Neuropsychology:Adult*. 2018;25(2):110-9.  
6  
7
- 8  
9 12. Kruse AJ, Nugent AS, Peterson AR. Using sideline concussion tests in the emergency  
10 department. *Open Access Emergency Medicine*. 2018;10:113-21.  
11  
12
- 13 13. Luoto TM, Silverberg ND, Kataja A, Brander A, Tenovuo O, Öhman J, et al. Sport concussion  
14 assessment tool 2 in a civilian trauma sample with mild traumatic brain injury. *Journal of*  
15 *Neurotrauma*. 2014;31(8):728-38.  
16  
17
- 18 14. Silverberg ND, Luoto TM, Öhman J, Iverson GL. Assessment of mild traumatic brain injury  
19 with the King-Devick Test® in an emergency department sample. *Brain Injury*. 2014;28(12):1590-3.  
20  
21  
22
- 23 15. Alsalaheen B, Stockdale K, Pechumer D, Broglio SP. Validity of the Immediate Post  
24 Concussion Assessment and Cognitive Testing (ImPACT). *Sports Medicine*. 2016;46(10):1487-501.  
25  
26  
27
- 28 16. Nelson LD, Furger RE, Gikas P, Lerner EB, Barr WB, Hammeke TA, et al. Prospective, Head-to-  
29 Head Study of Three Computerized Neurocognitive Assessment Tools Part 2: Utility for Assessment  
30 of Mild Traumatic Brain Injury in Emergency Department Patients. *Journal of the International*  
31 *Neuropsychological Society : JINS*. 2017;23(4):293-303.  
32  
33  
34
- 35 17. Shores EA, Lammel A, Hullick C, Sheedy J, Flynn M, Levick W, et al. The diagnostic accuracy of  
36 the Revised Westmead PTA Scale as an adjunct to the Glasgow Coma Scale in the early identification  
37 of cognitive impairment in patients with mild traumatic brain injury. *Journal of neurology,*  
38 *neurosurgery, and psychiatry*. 2008;79(10):1100-6.  
39  
40  
41  
42
- 43 18. Toman E BA, Preece A, Yeo D, Belli A, Welbury R, Hammond D. Screening for concussion in  
44 the Emergency Department of a regional Major Trauma Centre; audit and analysis of 500 patients.  
45 2018.  
46  
47  
48
- 49 19. Myers K, Kondamudi N, Hartsgrove C, Weingart A. 217 Making the Diagnosis of Concussion  
50 in the Emergency Department: Are We Hitting the Mark? *Annals of Emergency Medicine*. 2017;70(4,  
51 Supplement):S87.  
52  
53  
54
- 55 20. Hammond D, Welbury R, Sammons G, Toman E, Harland M, Rice S. How do oral and  
56 maxillofacial surgeons manage concussion? *The British journal of oral & maxillofacial surgery*.  
57 2018;56(2):134-8.  
58  
59  
60

- 1  
2  
3 21. Gennarelli T. Abbreviated Injury Scale (c) 2005 Update 2008. 2008.  
4
- 5  
6 22. Diccico-Bloom B, Crabtree BF. The qualitative research interview. Medical education.  
7  
8 2006;40(4):314-21.  
9
- 10 23. Lancaster GA, Dodd S, Williamson PR. Design and analysis of pilot studies: recommendations  
11  
12 for good practice. Journal of evaluation in clinical practice. 2004;10(2):307-12.  
13
- 14 24. Browne RH. On the use of a pilot sample for sample size determination. Statistics in  
15  
16 medicine. 1995;14(17):1933-40.  
17
- 18  
19 25. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ):  
20  
21 a 32-item checklist for interviews and focus groups. International Journal for Quality in Health Care.  
22  
23 2007;19(6):349-57.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **FIGURE LEGENDS**  
4  
5  
6

7 **Figure 1. CISG definition of concussion and ACRM definition of mTBI**  
8  
9

10 **Figure 2. Study protocol flowsheet**  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



---

**Concussion in Sport Group definition of concussion**

- History of direct blow to the head, face, neck or elsewhere on the body with an “impulsive” force transmitted to the head
  - History of rapid onset of short-lived impairment of neurologic function that resolves spontaneously
  - No evidence of structural abnormality to the brain seen on standard neuroimaging
  - LOC for no longer than 30 minutes
  - GCS of 13 or higher on presentation
  - PTA for no longer than 24 hrs
- 

**American Congress of Rehabilitation Medicine definition of mTBI**

A patient with mild traumatic brain injury is a person who has had a traumatically induced physiological disruption of brain function, as manifested by at least one of the following:

1. Any period of loss of consciousness;
  2. Any loss of memory for events immediately before or after the accident;
  3. Any alteration in mental state at the time of the accident (eg, feeling dazed, disoriented, or confused); and
  4. Focal neurological deficit(s) that may or may not be transient; but where the severity of the injury does not exceed the following:
    - loss of consciousness of approximately 30 minutes or less;
    - after 30 minutes, an initial Glasgow Coma Scale (GCS) of 13–15; and
    - posttraumatic amnesia (PTA) not greater than 24 hours
- 

LOC: loss of consciousness; GCS: Glasgow Coma Scale; PTA: post-traumatic amnesia; mTBI: mild traumatic brain injury

Figure 1. CISG definition of concussion and ACRM definition of mTBI

221x253mm (192 x 192 DPI)




Figure 2. Study protocol flowsheet

86x101mm (192 x 192 DPI)

# BMJ Open

## The CONcussion in non-aThletes; Assessment of CognITion and Symptomatology (CONTACTS) study protocol: An exploratory cohort study investigating the utility of sports concussion assessment tools and salivary micro-RNAs to diagnose concussion in NHS patients

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-062030.R2
Article Type:	Protocol
Date Submitted by the Author:	31-Aug-2022
Complete List of Authors:	Toman, Emma; University of Birmingham; University Hospitals Birmingham NHS Foundation Trust Riley, Max; University of Birmingham, Medical School Hodgson, Sam; University of Birmingham, Medical School Yakoub, Kamal; University Hospitals Birmingham NHS Foundation Trust, NIHR SRMRC Cooper, Lauren; University Hospitals Birmingham NHS Foundation Trust Bishop, Jon; University of Birmingham, Medical Statistician Naumann, David; Royal Centre for Defence Medicine; University Hospitals Birmingham NHS Foundation Trust, General Surgery Welbury, Richard; University of Central Lancashire, School of Dentistry Hammond, Douglas; Blackpool Teaching Hospitals NHS Foundation Trust, Department of Oral and Maxillofacial Surgery Di Pietro, Valentina; University of Birmingham, Institute of Inflammation and Ageing Belli, Antonio; NIHR Surgical Reconstruction and Microbiology Research Centre, Neurosurgery; University of Birmingham, School of Clinical and Experimental Medicine
<b>Primary Subject Heading</b>:	Emergency medicine
Secondary Subject Heading:	Surgery
Keywords:	ACCIDENT & EMERGENCY MEDICINE, Neurological injury < NEUROLOGY, NEUROSURGERY, TRAUMA MANAGEMENT

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6  
7  
8  
9

1 **The CONcussion in non-aThletes; Assessment of CogniTion and**  
2 **Symptomatology (CONTACTS) study protocol: An exploratory cohort study**  
3 **investigating the utility of sports concussion assessment tools and salivary**  
4 **micro-RNAs to diagnose concussion in NHS patients**

10  
11  
12  
13  
14  
15

5 *Emma Toman*,<sup>1,2,3</sup> Max Riley,<sup>4</sup> Sam Hodgson,<sup>4</sup> Kamal M Yakoub,<sup>2</sup> Lauren Cooper,<sup>2</sup> Jon Bishop,<sup>2,5</sup> David  
6 N Naumann,<sup>6,7</sup> Richard Welbury,<sup>8</sup> Douglas Hammond,<sup>9</sup> Valentina Di Pietro,<sup>1</sup> Antonio Belli<sup>1,2,3</sup>

16  
17  
18

9 *Corresponding author:*

19  
20  
21  
22  
23  
24

10 *Ms. Emma Toman*

11 *4<sup>th</sup> Floor, NIHR Surgical Reconstruction and Microbiology Research Centre, Institute of Translational*  
12 *Medicine, Heritage Building, Mindelsohn Way. Edgbaston, Birmingham, B15 2WB*  
13 *ekt635@student.bham.ac.uk*

- 25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47
- 15 1. Neurotrauma and Ophthalmology Research Group, Institute of Inflammation and Ageing,  
16 University of Birmingham, Birmingham, UK
  - 17 2. NIHR Surgical Reconstruction and Microbiology Research Centre, University Hospitals  
18 Birmingham NHS Foundation Trust, Birmingham, UK
  - 19 3. Department of Neurosurgery, University Hospitals Birmingham NHS Foundation Trust,  
20 Birmingham, UK
  - 21 4. College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK
  - 22 5. Institute of Applied Health Research, University of Birmingham, Birmingham, UK
  - 23 6. Royal Centre for Defence Medicine, Birmingham, UK
  - 24 7. Department of General Surgery, University Hospitals Birmingham NHS Foundation Trust,  
25 Birmingham, UK
  - 26 8. School of Dentistry, University of Central Lancashire, Preston, UK
  - 27 9. Department of Oral and Maxillofacial Surgery, Blackpool Teaching Hospitals NHS Foundation  
28 Trust, Blackpool, UK

48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

30 **Word count: 3338**

31  
32

1  
2  
3 **33 ABSTRACT**  
4  
5

6 34

7  
8 **35 Introduction:**  
9

10 36 Concussion is a complex pathophysiological process with a wide range of non-specific signs and  
11  
12 37 symptoms. There are currently no objective diagnostic tests to identify concussion, and diagnosis  
13  
14 38 relies solely on history and examination. Recent research has identified a unique panel of micro-  
15  
16 39 RNAs (miRNAs) that distinguish between concussed and non-concussed rugby players. This study  
17  
18 40 aims to assess the diagnostic utility of salivary miRNAs in concussion for a sample of UK National  
19  
20 41 Health Service (NHS) patients, and whether well-established sports-related concussion (SRC)  
21  
22 42 assessment tools may be translated into the Emergency Department (ED).  
23  
24  
25

26 43

27  
28 **44 Methods and analysis:**  
29

30 45 CONTACTS is a single-centre, prospective, two-phase cohort study. The concussed cohort will consist  
31  
32 46 of participants with maxillofacial trauma and concurrent concussion. The control cohort will consist of  
33  
34 47 participants with isolated limb trauma and no evidence of concussion. Participants will be recruited in  
35  
36 48 the ED and saliva samples will be taken to identify the presence of miRNAs. The SRC assessments being  
37  
38 49 investigated include the Sports Concussion Assessment Test version 5 (SCAT5), the Immediate Post-  
39  
40 50 Concussive Assessment and Cognitive Test (ImPACT), and the ImPACT Quick. Follow-up will be at 24-  
41  
42 51 48 hours in-hospital and remotely via telephone and email at 14 days and 6 months.  
43  
44  
45

46 52

47  
48 **53 Ethics and dissemination:**  
49

50 54 Ethical approval was granted in February 2021 by the West Midlands - Coventry & Warwickshire  
51  
52 55 Research Ethics Committee (ref 20/WM/0299). The investigators intend to submit their study findings  
53  
54 56 for publication in peer-reviewed journals and to disseminate study findings via presentation at  
55  
56 57 academic meetings. The results will also form part of a doctorate thesis, registered at the University  
57  
58 58 of Birmingham.  
59  
60

1  
2  
3 59  
4  
5 60  
6  
7  
8 61  
9  
10  
11 62  
12  
13 63  
14  
15 64  
16  
17 65  
18  
19 66  
20  
21 67  
22  
23 68  
24  
25 69  
26  
27 70  
28  
29 71  
30  
31 72  
32  
33 73  
34  
35 74  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## **STRENGTHS AND LIMITATIONS OF THIS STUDY**

- Incorporated feasibility phase to ensure the study is correctly powered
- Pragmatic design that allows assessment of potential clinical utility
- Traditionally excluded groups (older patients, those suffering from mental health conditions and concurrent intoxication) are to be included, to improve the translation into clinical practice
- COVID may limit the amount of time patients are in ED and so the design may need to be adapted
- Those with premorbid neurological or cognitive issues were unable to be included in this study which may limit the translation of any findings into clinical practice

## 75 INTRODUCTION

76

### 77 **Background and previous literature:**

78 Concussion is defined as “a complex pathophysiological process affecting the brain, induced by  
79 traumatic biomechanical forces”. (1) Signs and symptoms are nonspecific and are largely categorised  
80 into physical, cognitive, behavioural, and sleep. The Concussion in Sport Group (CISG) and the  
81 American Congress of Rehabilitation Medicine (ACRM) provide clear definitions of concussion and  
82 mild traumatic brain injury (mTBI) with clinical criteria that are summarised in Figure 1. (1, 2)

83 Each year 1.4 million people present to the Emergency Department (ED) in England and Wales with  
84 traumatic brain injury (TBI). (3) Since 90% of TBI cases are classified as mild in severity (4) and have an  
85 estimated lifetime cost of \$5,299, (5) concussion represents an extensive financial burden and is a  
86 substantial public health concern.

87 Diagnosis remains the main stumbling block in the management of concussion. There is currently no  
88 objective diagnostic test in clinical practice to identify the condition, and therefore diagnosis relies  
89 solely on history and examination. This poses difficulty where there are no witnesses to the event or  
90 the patient suffers from existing cognitive, neurological, or psychiatric disorders. The CISG has  
91 suggested that no single investigation should be used to diagnose concussion. Instead, several  
92 techniques should be used in combination with clinical judgement. (1) Two such widely accepted tools  
93 include the paper-based Sports Concussion Assessment Tool 5<sup>th</sup> edition (SCAT5) (6) and the  
94 computerised neurocognitive Immediate Post-Concussive Assessment and Cognitive Test (ImPACT).  
95 (7) Combined, these tools assess a wide variety of domains that can be affected by concussion  
96 including physical signs, symptoms, memory, concentration, balance, gait, reaction time, and  
97 attention.

1  
2  
3 98 Selection bias is the most common drawback of applying existing evidence to non-athletes. Older  
4  
5 99 people, those under the influence of alcohol or drugs, and patients with existing cognitive,  
6  
7  
8 100 neurological or psychiatric conditions have traditionally been excluded from previous studies. This  
9  
10 101 means that any prior findings may not apply to the overall UK National Health Service (NHS) population  
11  
12 102 presenting to services with concussion.

13  
14  
15 103 In addition to diagnosis, the follow-up of concussed patients within the NHS needs to be addressed.  
16  
17 104 The main difficulty in following up such individuals is the sheer number of patients suffering  
18  
19  
20 105 concussions. This would make face-to-face clinic follow-up of all patients a huge logistical challenge  
21  
22 106 and costly to an already cash-strapped NHS. Innovative methods of follow-up should be researched  
23  
24 107 and would likely involve remote reviews, as have become more common since the COVID-19  
25  
26 108 pandemic.

27  
28  
29  
30 109

### 31 32 33 110 **Salivary microRNAs (miRNAs)**

34  
35  
36 111 Salivary miRNAs have recently been identified as the most promising biomarker in the identification  
37  
38 112 of concussion in sport. miRNAs are non-coding fragments of RNA that play an important role in gene  
39  
40  
41 113 expression. (8) The most significant study so far in the investigation of salivary miRNA was the Study  
42  
43 114 of Concussion in Rugby Union through MicroRNAs; the “SCRUM study”, results of which were  
44  
45 115 published in 2021. This study found that a panel of 14 miRNAs successfully identified concussed rugby  
46  
47 116 players from those with a negative concussion assessment, non-injured controls, and musculoskeletal  
48  
49 117 injured controls. The miRNA panel was able to differentiate concussed participants from the other  
50  
51 118 groups immediately after the game (AUC 0.91, 95% CI 0.81 to 1) and 36–48 hours later (AUC 0.94,  
52  
53 119 95% CI 0.86 to 1). (9) These findings have significant implications for use in professional sports.  
54  
55  
56 120 Therefore it may be of use in non-athletes to detect concussion in the ED. Salivary miRNAs are worthy  
57  
58  
59  
60



1  
2  
3 121 of further investigation in the non-athlete setting where there are a far greater variation in age, and  
4  
5 122 physical and cognitive baseline characteristics of patients presenting with a head injury.  
6  
7

8 123  
9

#### 10 11 124 **Sports Concussion Assessment Tool 5<sup>th</sup> edition (SCAT5)** 12

13  
14 125 The SCAT5 is the most recent version of the SCAT, based on a systematic review of recent research  
15  
16 126 and expert panel input as part of the 5th International Consensus Conference on Concussion in Sport  
17  
18 127 held in Berlin in 2016. (1) The SCAT5 is a widely used tool used in the assessment of sports-related  
19  
20 128 concussion in patients 13 years or older and should take no less than 10 minutes to perform. The  
21  
22 129 diagnostic utility of the SCAT decreases after 3–5 days and has limited utility in tracking the recovery  
23  
24 130 of patients. (6) The assessment should be conducted by healthcare professionals only and is not  
25  
26 131 designed to be a standalone tool in the diagnosis of concussion.  
27  
28  
29

30  
31 132 Very few studies using SCAT in non-athlete populations have been published most data coming from  
32  
33 133 adolescent athletes. A shared finding across non-athlete studies is that symptom number and severity  
34  
35 134 seem to provide the most diagnostic accuracy for discriminating between concussed and control  
36  
37 135 patients. (10-14) The balance assessment is not well tolerated in non-athletes (12) and poses obvious  
38  
39 136 problems where the control sample have suffered limb injury. Very few studies have reported  
40  
41 137 individual elements of the SCAT assessment, with the majority combining all non-symptom sections  
42  
43 138 of the test to provide a Standardised Assessment of Concussion (SAC) score.  
44  
45  
46

47 139  
48  
49

#### 50 51 140 **Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT)** 52

53  
54 141 The ImPACT is a computer-based neurocognitive assessment widely used of professional sports. (7)  
55  
56 142 The ImPACT should be administered by a healthcare professional and is validated for patients aged  
57  
58 143 12-59 years. The test should take 20-25 minutes to administer and considers several different  
59  
60

1  
2  
3 144 assessment domains. As with the SCAT5, the ImPACT is not designed to be used as a standalone  
4  
5 145 diagnostic tool. The ImPACT ,provides composite domain scores for verbal memory, visual memory,  
6  
7 146 reaction time, processing speed and impulse control. Details of specific tests and how composite  
8  
9  
10 147 scores are calculated are included in Table 1.

11  
12  
13 148 **Table 1. ImPACT composite score calculations**

ImPACT composite score	Calculation
Verbal memory	Average of these scores: <ul style="list-style-type: none"> <li>• Word Memory total percent correct (immediate + delay) / 2</li> <li>• Symbol Match (hidden symbols)/9*100</li> <li>• Three letters Total letters correct</li> </ul>
Visual memory	Average of the following scores: <ul style="list-style-type: none"> <li>• X's and O's-total correct (interference) total/4</li> <li>• Design memory-total percent correct (immediate + delay) / 2</li> </ul>
Reaction time	Average of these scores: <ul style="list-style-type: none"> <li>• X's and O's average correct RT</li> <li>• Symbol Match average correct RT/3</li> <li>• Colour Match average correct RT</li> </ul>
Processing speed	Average of the following scores: <ul style="list-style-type: none"> <li>• X's and O's-total correct (interference) total/4</li> <li>• Three letters-average counted correctly*3</li> </ul>
Impulse control	Sum of the following scores: <ul style="list-style-type: none"> <li>• X's and O's-total incorrect –interference</li> <li>• Colour match total commissions</li> </ul>

14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50 149  
51  
52  
53  
54 150 This requires a pre-injury assessment to which post-concussion scores are compared. The program  
55  
56 151 calculates a reliable change index (RCI) score and where this exceeds the expected range in variation,  
57  
58 152 identifies it as abnormal. (7) The ImPACT Quick programme was designed for use at the pitch side and  
59  
60

1  
2  
3 153 to aid in removal-from-play decisions. Rather than relying on a pre-test score to compare, the results  
4  
5 154 are presented as percentile scores from a large representative sample of individuals with no history  
6  
7  
8 155 of concussion.

9  
10  
11 156 A recent literature review examining the validity of the ImPACT revealed that although the tool  
12  
13 157 demonstrated sound convergent validity, research describing discriminant validity and diagnostic  
14  
15 158 accuracy was either inconclusive or scanty. (15) This provides support for further studies in this area.  
16  
17  
18 159 Very few of the studies included in the review concerned the use of the ImPACT in non-athlete  
19  
20 160 populations and three of the sixty-nine studies analysed the use of the ImPACT in concussed versus  
21  
22 161 controls suffering orthopaedic injuries.

23  
24  
25 162 Non-athlete studies using the ImPACT have produced conflicting results. A 2017 American study  
26  
27 163 recruited 94 concussed patients and 80 matched-trauma controls from ED and performed the ImPACT  
28  
29 164 within 72 hours of injury, 15 days, and 45 days. (16) No significant difference in composite scores were  
30  
31  
32 165 found between groups at any of the time points. By comparison, an Australian study assessing 79  
33  
34 166 concussed patients to 86 trauma control patients in the ED found significant differences in all 5  
35  
36 167 composite domain scores. (17)

37  
38  
39  
40 168

41  
42  
43 169

44  
45  
46 170

47  
48  
49 171

50  
51  
52 172 **RATIONALE**

53 173 Previous work suggests that concussion remains underdiagnosed in the ED (18, 19) and patients may  
54  
55  
56 174 not be followed up adequately in clinical practice. (20) This may reflect the complex nature of  
57  
58 175 diagnosing and monitoring concussion but may also demonstrate the lack of NHS resources allocated  
59  
60

1  
2  
3 176 towards concussion care. Additional common barriers to screening for concussion in NHS patients  
4  
5 177 such as intoxication and dementia complicate recognition and diagnosis further. (18) It is important  
6  
7 178 therefore to assess whether well-established SRC assessment tools may be translated into the non-  
8  
9  
10 179 sporting population of the NHS. A longer-term qualitative review of the tools would add depth to  
11  
12 180 existing data and also indicate the willingness of non-athletes to engage in these tests using telephone  
13  
14 181 and email reviews.

15  
16  
17 182 Currently, the National Institute for Health and Care Excellence (NICE) guidelines concerning head  
18  
19 183 injury focus on appropriate triage and acute management. No guidelines exist regarding follow-up or  
20  
21 184 referral of patients with ongoing symptoms. More innovative ways of monitoring recovery and  
22  
23 185 symptoms in such patients need to be developed, ideally remotely. A concussion assessment that is  
24  
25 186 clinically accurate and that patients can—and want to—perform at home could revolutionise the  
26  
27 187 possibilities in which secondary care clinicians could manage these patients.

28  
29  
30  
31  
32 188

33  
34  
35 189

36  
37 190  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 191 **METHODS AND ANALYSIS**

192

### 193 **Study Design**

194 CONTACTS is a prospective cohort study investigating the use of sports concussion assessment tools  
195 and the diagnostic utility of salivary miRNAs in concussed versus control adult participants following  
196 non-sporting maxillofacial trauma. It will commence with a phase 1, feasibility study followed by a  
197 phase 2, substantive study if progression criteria are met. Both phases will take place at the Queen  
198 Elizabeth Hospital Birmingham (QEHB) as a single-centre study. Participants will be followed up for 6  
199 months post recruitment. Phase 1 commenced on 21/07/2021 and the planned end date for  
200 recruitment to all study phases is 01/10/2023.

201 Patients of interest are adult patients who require hospital admission following non-sporting isolated  
202 maxillofacial trauma. Recruiting patients with maxillofacial trauma to the concussion arm ensures that  
203 there is objective evidence of head injury having occurred. This also provides a sample of patients who  
204 require admission to hospital, whereas isolated concussion does not usually require admission to  
205 hospital.

206

### 207 **Eligibility Criteria**

208 For patients with isolated concussion, the standard clinical care would be discharge from the ED with  
209 a responsible adult and suitable head injury advice. To optimise the rate of follow-up of participants,  
210 only patients requiring admission will be recruited. To ensure that all participants in the concussion  
211 arm have suffered an impact to the head, face, or neck (as required for concussion diagnosis according  
212 to CISG definition), only patients with maxillofacial injury will be recruited. Brain imaging is not an  
213 inclusion criterion as not all patients suffering from concussion require CT scanning (3) and we wish  
214 to reflect clinical practice in this pragmatic study design. The control arm will consist of participants  
215 having suffered an isolated limb injury. Inclusion and exclusion criteria are summarised in table 2.

216

217 **Table 2. Summary of eligibility criteria for the CONTACTS study**

<b>Cohort</b>	<b>Inclusion</b>	<b>Exclusion</b>
<i>Both</i>	<p>≥16 years old</p> <p>Requires admission to QEHB</p> <p>Injury sustained within 24 hrs of presentation</p>	<p>Police custody</p> <p>Prisoner</p> <p>Evidence of intracranial injury on CT (if performed as part of standard clinical care)</p> <p>Significant communication barriers</p> <p>Not fluent in the English language</p> <p>Prior medical history of neurological or cognitive impairment</p>
<i>Concussed</i>	<p>Diagnosis of maxillofacial injury</p> <p>Clinical features consistent with a diagnosis of concussion:</p> <ul style="list-style-type: none"> <li>- History of direct blow to the head, face, neck, or elsewhere on the body with an “impulsive” force transmitted to the head</li> <li>- History of rapid onset of short-lived impairment of neurologic function that resolves spontaneously</li> <li>- No evidence of structural abnormality to the brain seen on standard neuroimaging</li> <li>- LOC ≤ 30 minutes</li> <li>- GCS ≥ 13 on presentation</li> <li>- PTA ≤ 24 hrs</li> </ul>	<p>LOC &gt; 30mins</p> <p>GCS &lt; 13 on presentation</p> <p>PTA lasting &gt; 24 hrs (assess at 24 hrs)</p> <p>Mechanism of injury due to organised sports activity</p>
<i>Control</i>	Diagnosis of isolated limb injury	<p>History of TBI</p> <p>Clinical features consistent with a diagnosis of concussion according to CISG criteria and ACRM definition</p> <p>Insufficiency, open, femoral, or tibia-fibula fracture</p>

218 LOC (loss of consciousness), GCS (Glasgow Coma Scale), PTA (post-traumatic amnesia)

219

1  
2  
3 220 This is an observational study and therefore there will be no study-related interventions in the clinical  
4  
5 221 care of participants. The SCAT5 and ImpACT tools will be used by study investigators to assess  
6  
7 222 participants in addition to their routine clinical care. Salivary sample collection is a non-invasive  
8  
9  
10 223 procedure.

11  
12  
13 224 Concussed participants will be compared to participants who had sustained isolated limb trauma as  
14  
15 225 controls. Patients with isolated limb injuries are a suitable control group because they have similar  
16  
17 226 Abbreviated Injury Scale (AIS) severity codes to concussion and facial injuries. (21) Isolated lower limb  
18  
19 227 injuries requiring admission will also receive similar management to the concussed group such as  
20  
21  
22 228 operative interventions and pain management.

23  
24 229

### 25 26 27 230 **Patient and public involvement**

28  
29  
30 231 A consultation with Patient and Public Involvement and Engagement (PPIE)- the Trauma Advisory  
31  
32 232 Group (TAG) (previously known as the Accident, Burns, and Critical Care group) of the National  
33  
34 233 Institute for Health Research, Surgical Reconstruction and Microbiology Research Centre (NIHR  
35  
36 234 SRMRC) was undertaken in June 2018. The TAG consists of around 20 members and is a collective of  
37  
38  
39 235 patients, family, and members of the public with a mixed experience of trauma, burns, and critical  
40  
41  
42 236 care. The age of members ranges from mid-twenties to retirement and the majority have been  
43  
44 237 involved in clinical research studies.

45  
46  
47 238 Overall, there was very positive feedback from the group about the study. Members who have been  
48  
49 239 involved in previous clinical studies stated they liked the study design and expressed interest in joining  
50  
51 240 the study if they or members of their families were approached. Specifically, the group felt that the  
52  
53 241 time required to complete study assessments as a participant was reasonable and not too onerous.

54  
55  
56  
57 242

### 58 59 243 **Feasibility phase and progression criteria**

1  
2  
3 244 The feasibility phase (Phase 1) aims to recruit 30 patients within 6 months. Phase 1 will end after 6  
4  
5 245 months or following the 14-day post-injury time-point of participant number 30—whichever comes  
6  
7 246 sooner. Following the completion of phase 1, the study management group will meet to assess and  
8  
9 247 attribute a red, amber, or green status to the study:  
10  
11

12 248 **Red:** intractable issues that cannot be remedied; study should not progress to phase 2  
13  
14

15 249 **Amber:** remediable issues that require attention before progressing to phase 2  
16  
17

18 250 **Green:** no concerning issues that threaten the success of the trial; continue to phase 2 without  
19  
20 251 substantial amendment (minor amendments may be required).  
21

22 252

23  
24 253 Progression criteria are listed below:  
25  
26

27 254 1. The target recruitment rate is 5 participants per month. If fewer than 70% of the target  
28  
29 255 recruitment number (21 patients) have been recruited by month 6 of phase 1 without  
30  
31 256 identifiable and correctable cause it would not be feasible to progress to phase 2.  
32

33 257 2. Following phase 1, if the loss to follow up at the 24-48 hrs and 14-day time-points exceed 30%  
34  
35 258 in either arm without identifiable and correctable cause, it would not be feasible to progress  
36  
37 259 to phase 2 without substantial amendments to study design.  
38  
39

40 260  
41  
42

43 261  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 **262** **STUDY PROCEDURE**  
4

5  
6 **263** A summary of the eligibility criteria and recruitment process is contained in Figure 2.  
7

8  
9 **264**

10  
11 **265** **Participant identification**  
12

13  
14 **266** The research team will approach the potential participant only once eligibility has been confirmed by  
15

16 **267** the treating clinical (either Oral and Maxillofacial or Trauma and Orthopaedics) teams.  
17  
18

19  
20 **268**

21  
22 **269** **Screening**  
23

24  
25 **270** Discussion with the treating clinical team should confirm that the patient will require hospital  
26

27 **271** admission and there is a diagnosis of either maxillofacial injury or isolated limb injury. Any  
28

29 **272** computerised tomography (CT) head scan reports performed as a standard of clinical care must be  
30

31 **273** reviewed to confirm the presence or absence of intracranial injury (according to the eligibility criteria).  
32

33 **274** To confirm a diagnosis consistent with a concussion the CISG definition of concussion (1) and the  
34

35 **275** American Congress of Rehabilitation Medicine (ACRM) (2) definition of mTBI must be met.  
36  
37

38  
39 **276**  
40

41  
42 **277** **Consent**  
43

44  
45 **278** When potential participants fulfil eligibility criteria, they will be approached by a member of the  
46

47 **279** research team who will provide the patient information sheet and clarify any information from the  
48

49 **280** patient/relatives that may prevent recruitment. Wherever possible, informed consent will be obtained  
50

51 **281** from the patient,, however due to the nature of concussion, this may not be possible.  
52  
53

54  
55 **282** The process for obtaining consent in patients lacking capacity is outlined below:  
56

57  
58 **283** *Patient personal consultee available in hospital*  
59  
60

1  
2  
3 284 For patients lacking capacity, a personal consultee will be sought. If such a consultee is available in the  
4  
5 285 hospital, they will be provided with written information about the study and asked if they wish to  
6  
7 286 provide written agreement prior to enrolment.  
8  
9

10  
11 287 *Patient personal consultee not available in the hospital*  
12

13 288 For patients lacking capacity where no personal consultee is available in the hospital, enrolment will  
14  
15 289 be possible with written agreement from a nominated consultee. If a personal consultee becomes  
16  
17 290 available, then the study will be discussed with them, and written agreement gained for the  
18  
19 291 participant to continue in the study.  
20  
21

22 292 *Patients who regain capacity*  
23

24 293 Where patients regain capacity following either personal or nominated consultee agreement they will  
25  
26 294 be informed about the study and asked for consent to continue as a participant.  
27  
28

29 295 If at any time either the personal consultee or participant choose to withhold consent or written  
30  
31 296 agreement, then the participant will be withdrawn from the study. An agreement with the participant  
32  
33 297 or personal consultee will be made at this time-point as to whether they give permission for the use  
34  
35 298 of any data already collected as part of the study or whether they wish for this to be destroyed. If the  
36  
37 299 data have been analysed, it will not be able to be destroyed and the participant will be informed.  
38  
39  
40

41 300 *Personal consultee definition*  
42

43 301 An individual who knows the patient well but is not acting in a professional or paid capacity and  
44  
45 302 someone whom the person who lacks capacity would trust with important decisions about their  
46  
47 303 welfare, for example a family member or close friend.  
48  
49  
50

51 304 *Nominated consultee definition*  
52

53 305 An independent healthcare professional (IHP) who is prepared to be consulted by the researcher but  
54  
55 306 has no connection with the research study.  
56  
57  
58

59 307  
60

1  
2  
3 **308 Baseline and study assessment data**  
4  
5

6 **309** All participants will have a medical history and clinical examination as part of routine standard of care  
7  
8 **310** and the following will be recorded in the Case Report Form (CRF). Tables 3 and 4 contain summaries  
9  
10 **311** of relevant baseline data and study assessment to be collected at timepoints in the ED, at 24-28hours,  
11  
12  
13 **312** 14 days and 6 months.  
14

15 **313** No specific study “test conditions” will be imposed during the study assessments to continue the  
16  
17 **314** pragmatic nature of the study. Study assessments will be conducted in the real-life clinical  
18  
19 **315** environment to provide a true reflection of the translatability of any study results.  
20  
21  
22

23 **316**  
24  
25

26 **317 Table 3. Baseline data to be collected in the Emergency Department**  
27  
28

<i>Standard of care</i>	Patient demography
	Past medical history (including co-morbidities and medications)
	Injury related events (time of injury, mechanism of injury, subsequent signs/symptoms)
	Neurological status
	Diagnosed injury
	CT head findings (only if performed as standard of care)
	Medications received
<i>Study related data</i>	ImPACT Quick
	SCAT5
	Contact details (telephone and email address)
	Educational level (number of years of education completed)
	Diagnosis of learning disability or Attention Deficit Hyperactivity Disorder
	Level of intoxication (number of units of alcohol consumed as reported by the participant)

---

History of concussion or other head injury

---

*Study related sample*      Saliva sample

---

318

319

320 **Table 4. Summary of study assessments at 24-48h, 14 days and 6 months**

---

<i>24-48 hours</i>	ImPACT
	SCAT5
	Operative interventions
	Neurological status
	Presence or absence of PTA
	CT head findings (only if performed as standard of care)
	Saliva sample
<i>14 days</i>	ImPACT performed remotely (link sent via email)
	SCAT5 symptoms checklist (via telephone)
<i>6 months</i>	SCAT5 symptoms checklist (via telephone)
	Functional data (return to work, return to fitness)

---

321

322

323 **Qualitative assessment**

324 A qualitative telephone interview will be conducted at 6 months following enrolment. As suggested  
 325 by the TAG PPIE group, where possible, the interviewer will be the same researcher who has had prior  
 326 contact with the patient, either in-hospital or via telephone. The format will be of “in-depth semi-  
 327 structured” interviews on an individual basis. These are interviews organised around a set of  
 328 predetermined open-ended questions, with other questions generated from subsequent dialogue  
 329 between interviewer and interviewee. (22) The interviews will be conducted via telephone and  
 330 recorded for subsequent analysis using NVivo analysis software.

1  
2  
3 331  
4  
5

6 332 **Collection, storage and testing of saliva samples**  
7

8  
9 333 The samples will be collected in OCR-100 saliva collection pots containing a proprietary miRNA

10  
11 334 stabilising solution. Saliva is collected using a standardised technique where the user gently rubs the

12  
13 335 sponge swab along the lower gums ten times on either side of the mouth. In these pots samples will

14  
15 336 be stable at room temperature for 8 weeks and will be transferred to the laboratory within 1 week

16  
17 337 of collection to comply with Human Tissue Act regulations. The samples will be transported to the

18  
19 338 laboratory at the University of Birmingham (UoB) and stored in the -80 degrees freezer. miRNA

20  
21 339 profile will be analysed using standard qPCR technique. Once the study has been completed all

22  
23 340 samples will be destroyed.  
24  
25

26  
27 341

28  
29 342 **Sample size calculation**  
30

31  
32 343 As phase 1 is an exploratory cohort study, no formal sample size calculation has been performed.

33  
34 344 Following recommendations for pilot studies, 30 patients or more are typically required to obtain

35  
36 345 estimates of the parameters needed for sample size estimation. (23, 24) Hence, phase 1 of this study

37  
38 346 will aim to recruit 30 patients to estimate the mean and SD of the 7 SCAT5 domain scores and 3

39  
40 347 composite ImPACT Quick domain scores in the ED. This will also allow the recruitment and retention

41  
42 348 rates to be estimated with 95% confidence interval maximum widths of 27% and 35% respectively.  
43  
44

45  
46 349 The sample size for phase 2 will be calculated based on the observed distributions of outcome scores

47  
48 350 in phase 1.  
49  
50

51 351

52  
53  
54 352 **Statistical analysis plan**  
55

56  
57 353 The data analysis for phase 1 will be descriptive and mainly focus on confidence interval estimation,

58  
59 354 with no hypothesis testing performed. Data will be explored to assess the key feasibility aspects of  
60

1  
2  
3 355 undertaking a full-scale study on the clinical accuracy of concussion assessment tools in patients with  
4  
5 356 non-sporting trauma.  
6  
7

8 357 Dichotomous feasibility measures, such as the recruitment and retention rates, as well as data  
9  
10 358 completeness will be reported as numbers and percentages. Where appropriate, these values will be  
11  
12 359 summarised across patient groups.  
13  
14

15 360 Phase 1 data will inform the selection of the primary outcomes for the main study and provide  
16  
17 361 estimates for sample size calculations. Outcome data on concussion assessment tools are collected in  
18  
19 362 ED, at 24-48 hours, 14 days and 6 months post-recruitment. Analysis methods will be chosen according  
20  
21 363 to the data type of the outcome under investigation, in brief:  
22  
23

24  
25 364 • *Continuous endpoints (e.g., SCAT5 domain scores)*: These data will be summarised using  
26  
27 365 means and standard deviations, with differences in means with 95% confidence intervals  
28  
29 366 reported. Longitudinal plots of the data over time will also be constructed for visual  
30  
31 367 presentation of the data.  
32  
33

34  
35 368 • *Time to Event endpoints (e.g., time to return to work or recovery)*: The numbers of participants  
36  
37 369 and percentages experiencing the event will be summarised over time between groups.  
38  
39 370 Kaplan-Meier curves will be constructed for visual presentation of time-to-event data.  
40  
41

42 371  
43  
44  
45 372 The phase 2 data will be used to undertake exploratory analyses of concussion assessment tool  
46  
47 373 domains adjusted for baseline demographics (age, education level, and gender) and level of self-  
48  
49 374 reported intoxication.  
50  
51

52 375  
53  
54  
55 376 **Primary outcome analysis (Phase 1)**  
56  
57  
58  
59  
60

1  
2  
3 377 The scores in the three ImPACT Quick domains (speed, memory and attention) and 7 SCAT5 domains  
4  
5 378 (symptoms number, symptom severity, orientation, immediate memory, concentration and balance  
6  
7 379 errors) will be summarised across the concussed and control groups in ED. These are continuous  
8  
9 380 outcomes, and a linear regression model adjusting for gender, educational level, age, and intoxication  
10  
11 381 level, will be used to calculate the adjusted mean differences and 95% confidence intervals.  
12  
13  
14 382 Unadjusted models will be used in the event of the adjusted models failing to converge.  
15  
16

17 383

### 19 384 **Secondary outcome analysis (Phase 2)**

21  
22 385 Continuous data (e.g., ImPACT and SCAT5 domain scores at specified time-points) will be analysed in  
23  
24 386 the same way as the primary outcome. The panel of 23 salivary miRNAs will be analysed as continuous  
25  
26 387 data in the same way as the primary outcome but using a Benjamin-Hochberg procedure to control  
27  
28 388 the false discovery rate when testing these multiple hypotheses. Time-to-event data (e.g., time to  
29  
30 389 recovery) will be analysed using the log-rank test with a Cox Proportional Hazard model used to  
31  
32  
33 390 calculate hazard ratios, if the assumptions of proportionality are met.  
34  
35

36 391

37 392

### 39 393 **Qualitative analysis**

41  
42 394 Interview data will be audio recorded for analysis using an encrypted audio recorder device. Formal  
43  
44 395 analysis will be performed using NVivo qualitative data analysis software. Thematic analysis will be  
45  
46 396 used, and some anonymised quotes will be included in the final report. Qualitative data will be  
47  
48  
49 397 reported according to consolidated criteria for reporting qualitative research (COREQ) guidelines. (25)  
50  
51

52 398

55 399

57 400

1  
2  
3 401 **ETHICS AND DISSEMINATION**  
4  
5

6 402 All study related data collected will be stored on NHS servers in accordance with the 1998 UK Data  
7  
8 403 Protection Act, UoB and University Hospitals Birmingham NHS Foundation Trust data handling and  
9  
10 404 maintenance guidelines. The Trust network has restricted physical access; data are stored under  
11  
12 405 coded file names and the local network has secure password access restricted to researchers involved  
13  
14  
15 406 with the study.  
16  
17

18 407 The study investigators intend to submit their study findings for publication in peer reviewed journals,  
19  
20 408 and to disseminate the findings via presentation at academic meetings/conferences. The results will  
21  
22 409 also form part of a doctorate thesis, registered at the University of Birmingham.  
23  
24

25 410 Ethical approval was granted in February 2021 (ref 20/WM/0299) by the West Midlands - Coventry &  
26  
27 411 Warwickshire Research Ethics Committee.  
28  
29

30 412  
31

32 413  
33

34 414  
35  
36

37 415  
38  
39

40 416  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 417 **CONTRIBUTORSHIP**  
4  
5

6 418 ET, JB, AB, VD, DNN, LC contributed to study design. ET, RW, DH, edited study design. ET, MR, DNN,  
7

8 419 VD, SH, KY contributed to manuscript preparation and editing. All authors agreed on final manuscript  
9

10 420 edit prior to submission.  
11  
12

13 421  
14

15 422  
16

17 423 **FUNDING STATEMENT**  
18  
19

20 424 Funding for microRNA analysis will be provided by Marker Diagnostics Ltd. Licenses for ImPACT®  
21

22 425 testing are funded by NIHR SRMRC.  
23  
24

25 426 Funding grant awards: not applicable.  
26  
27

28 427  
29  
30

31 428 **COMPETING OF INTERESTS**  
32  
33

34 429 Prof A Belli and Dr V Di Pietro are members of the research team and shareholders for Marker  
35

36 430 Diagnostics Ltd, the company providing the funding for the salivary miRNA tests.  
37  
38

39 431  
40  
41

42 432  
43  
44

45 433  
46  
47

48 434  
49  
50

51 435  
52  
53

54 436  
55  
56

57 437  
58  
59  
60

1  
2  
3 438 **REFERENCES**  
4  
5

6 439  
7

8  
9 440 1. McCrory P, Meeuwisse W, Dvorak J, Aubry M, Bailes J, Broglio S, et al. Consensus statement  
10 441 on concussion in sport-the 5(th) international conference on concussion in sport held in Berlin,  
11  
12 442 October 2016. British journal of sports medicine. 2017;51(11):838-47.  
13

14  
15 443 2. Definition of mild traumatic brain injury. The Journal of Head Trauma Rehabilitation.  
16 444 1993;8(3):86-7.  
17

18  
19 445 3. National Clinical Guideline C. National Institute for Health and Clinical Excellence: Guidance.  
20 446 Head Injury: Triage, Assessment, Investigation and Early Management of Head Injury in Children,  
21 447 Young People and Adults. London: National Institute for Health and Care Excellence (UK)  
22  
23  
24 448 Copyright (c) National Clinical Guideline Centre, 2014.; 2014.  
25  
26

27  
28 449 4. Rickels E, von Wild K, Wenzlaff P. Head injury in Germany: A population-based prospective  
29 450 study on epidemiology, causes, treatment and outcome of all degrees of head-injury severity in two  
30 451 distinct areas. Brain Inj. 2010;24(12):1491-504.  
31  
32

33  
34 452 5. Te Ao B, Brown P, Tobias M, Ameratunga S, Barker-Collo S, Theadom A, et al. Cost of  
35 453 traumatic brain injury in New Zealand: evidence from a population-based study. Neurology.  
36 454 2014;83(18):1645-52.  
37  
38

39  
40 455 6. Sport concussion assessment tool - 5th edition. British journal of sports medicine.  
41 456 2017;51(11):851-8.  
42  
43

44 457 7. Inc IA. ImPACT Applications Products San Diego: ImPACT Applications Inc; 2018 [cited 2018  
45 458 17th March]. Available from: <https://www.impacttest.com/products/>.  
46  
47

48 459 8. Ambros V. The functions of animal microRNAs. Nature. 2004;431:350.  
49

50  
51 460 9. Di Pietro V, O'Halloran P, Watson CN, Begum G, Acharjee A, Yakoub KM, et al. Unique  
52 461 diagnostic signatures of concussion in the saliva of male athletes: the Study of Concussion in Rugby  
53 462 Union through MicroRNAs (SCRUM). British journal of sports medicine. 2021;55(24):1395-404.  
54  
55

56  
57 463 10. Babl FE, Dionisio D, Davenport L, Baylis A, Hearps SJC, Bressan S, et al. Accuracy of  
58 464 Components of SCAT to Identify Children With Concussion. Pediatrics. 2017;140(2).  
59  
60

- 1  
2  
3 465 11. Bin Zahid A, Hubbard ME, Dammavalam VM, Balsler DY, Pierre G, Kim A, et al. Assessment of  
4 466 acute head injury in an emergency department population using sport concussion assessment tool–  
5 467 3rd edition. *Applied Neuropsychology:Adult*. 2018;25(2):110-9.  
6  
7  
8  
9 468 12. Kruse AJ, Nugent AS, Peterson AR. Using sideline concussion tests in the emergency  
10 469 department. *Open Access Emergency Medicine*. 2018;10:113-21.  
11  
12  
13 470 13. Luoto TM, Silverberg ND, Kataja A, Brander A, Tenovuo O, Öhman J, et al. Sport concussion  
14 471 assessment tool 2 in a civilian trauma sample with mild traumatic brain injury. *Journal of*  
15 472 *Neurotrauma*. 2014;31(8):728-38.  
16  
17  
18  
19 473 14. Silverberg ND, Luoto TM, Öhman J, Iverson GL. Assessment of mild traumatic brain injury  
20 474 with the King-Devick Test® in an emergency department sample. *Brain Injury*. 2014;28(12):1590-3.  
21  
22  
23  
24 475 15. Alsalaheen B, Stockdale K, Pechumer D, Broglio SP. Validity of the Immediate Post  
25 476 Concussion Assessment and Cognitive Testing (ImPACT). *Sports Medicine*. 2016;46(10):1487-501.  
26  
27  
28 477 16. Nelson LD, Furger RE, Gikas P, Lerner EB, Barr WB, Hammeke TA, et al. Prospective, Head-to-  
29 478 Head Study of Three Computerized Neurocognitive Assessment Tools Part 2: Utility for Assessment  
30 479 of Mild Traumatic Brain Injury in Emergency Department Patients. *Journal of the International*  
31 480 *Neuropsychological Society : JINS*. 2017;23(4):293-303.  
32  
33  
34  
35  
36 481 17. Shores EA, Lammel A, Hullick C, Sheedy J, Flynn M, Levick W, et al. The diagnostic accuracy of  
37 482 the Revised Westmead PTA Scale as an adjunct to the Glasgow Coma Scale in the early identification  
38 483 of cognitive impairment in patients with mild traumatic brain injury. *Journal of neurology,*  
39 484 *neurosurgery, and psychiatry*. 2008;79(10):1100-6.  
40  
41  
42  
43  
44 485 18. Toman E BA, Preece A, Yeo D, Belli A, Welbury R, Hammond D. Screening for concussion in  
45 486 the Emergency Department of a regional Major Trauma Centre; audit and analysis of 500 patients.  
46 487 2018.  
47  
48  
49  
50 488 19. Myers K, Kondamudi N, Hartsgrove C, Weingart A. 217 Making the Diagnosis of Concussion  
51 489 in the Emergency Department: Are We Hitting the Mark? *Annals of Emergency Medicine*. 2017;70(4,  
52 490 Supplement):S87.  
53  
54  
55  
56 491 20. Hammond D, Welbury R, Sammons G, Toman E, Harland M, Rice S. How do oral and  
57 492 maxillofacial surgeons manage concussion? *The British journal of oral & maxillofacial surgery*.  
58 493 2018;56(2):134-8.  
59  
60

- 1  
2  
3 494 21. Gennarelli T. Abbreviated Injury Scale (c) 2005 Update 2008. 2008.  
4  
5  
6 495 22. Diccico-Bloom B, Crabtree BF. The qualitative research interview. Medical education.  
7  
8 496 2006;40(4):314-21.  
9  
10 497 23. Lancaster GA, Dodd S, Williamson PR. Design and analysis of pilot studies: recommendations  
11  
12 498 for good practice. Journal of evaluation in clinical practice. 2004;10(2):307-12.  
13  
14 499 24. Browne RH. On the use of a pilot sample for sample size determination. Statistics in  
15  
16 500 medicine. 1995;14(17):1933-40.  
17  
18  
19 501 25. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ):  
20  
21 502 a 32-item checklist for interviews and focus groups. International Journal for Quality in Health Care.  
22  
23 503 2007;19(6):349-57.  
24  
25 504  
26  
27  
28 505  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 506 **FIGURE LEGENDS**  
4  
5

6  
7 507 **Figure 1. CISG definition of concussion and ACRM definition of mTBI**  
8  
9

10 508 **Figure 2. Study protocol flowsheet**  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

---

**Concussion in Sport Group definition of concussion**

- History of direct blow to the head, face, neck or elsewhere on the body with an “impulsive” force transmitted to the head
- History of rapid onset of short-lived impairment of neurologic function that resolves spontaneously
- No evidence of structural abnormality to the brain seen on standard neuroimaging
- LOC for no longer than 30 minutes
- GCS of 13 or higher on presentation
- PTA for no longer than 24 hrs

---

**American Congress of Rehabilitation Medicine definition of mTBI**

A patient with mild traumatic brain injury is a person who has had a traumatically induced physiological disruption of brain function, as manifested by at least one of the following:

1. Any period of loss of consciousness;
2. Any loss of memory for events immediately before or after the accident;
3. Any alteration in mental state at the time of the accident (eg, feeling dazed, disoriented, or confused); and
4. Focal neurological deficit(s) that may or may not be transient; but where the severity of the injury does not exceed the following:
  - loss of consciousness of approximately 30 minutes or less;
  - after 30 minutes, an initial Glasgow Coma Scale (GCS) of 13–15; and
  - posttraumatic amnesia (PTA) not greater than 24 hours

---

LOC: loss of consciousness; GCS: Glasgow Coma Scale; PTA: post-traumatic amnesia; mTBI: mild traumatic brain injury

Figure 1. CISG definition of concussion and ACRM definition of mTBI

221x253mm (192 x 192 DPI)




Figure 2. Study protocol flowsheet

86x101mm (192 x 192 DPI)

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	Line location
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1-4
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	33-58
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	77-187
Objectives	3	State specific objectives, including any prespecified hypotheses	39-42
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	191-259
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	197-200
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	207-228
		(b) For matched studies, give matching criteria and number of exposed and unexposed	n/a
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	308-330
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	124-167 308-330
Bias	9	Describe any efforts to address potential sources of bias	224-228
Study size	10	Explain how the study size was arrived at	342-350
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	376-390
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	352-390
		(b) Describe any methods used to examine subgroups and interactions	n/a
		(c) Explain how missing data were addressed	n/a
			protocol
		(d) If applicable, explain how loss to follow-up was addressed	n/a
			protocol
		(e) Describe any sensitivity analyses	n/a
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	n/a protocol
		(b) Give reasons for non-participation at each stage	n/a protocol
		(c) Consider use of a flow diagram	n/a protocol
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	n/a protocol
		(b) Indicate number of participants with missing data for each variable of interest	n/a protocol



		(c) Summarise follow-up time (eg, average and total amount)	n/a protocol
Outcome data	15*	Report numbers of outcome events or summary measures over time	n/a protocol
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	n/a protocol
		(b) Report category boundaries when continuous variables were categorized	n/a protocol
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	n/a protocol
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	n/a protocol
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	n/a protocol
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	62-72
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	n/a protocol
Generalisability	21	Discuss the generalisability (external validity) of the study results	n/a protocol
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	423-426

\*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.